Diagnostic methods

The method improves cancer screening by analyzing genetic data from multiple time points and adjusting diagnostic confidence indices to enhance the detection of genetic variations, addressing the limitations of current methods in sensitivity and accuracy.

JP7594522B2Active Publication Date: 2024-12-04GUARDANT HEALTH INC
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2021203136
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2015-05-01
Filing Date
2021-12-15
Publication Date
2024-12-04
Estimated Expiration
2036-04-29

AI Technical Summary

Technical Problem

Current cancer screening methods using cell-free nucleic acids are limited by the need for improved sensitivity and accuracy in detecting genetic variations, particularly at low frequencies and in the presence of noise and sequencing errors, which complicates the detection of genetic variants associated with cancer.

Method used

A method involving genetic analysis using a genetic analyzer to generate and compare genetic data from multiple time points, updating a diagnostic confidence index based on sequence read data, and adjusting test results to enhance the detection of genetic variations by increasing read depth and using a diagnostic confidence index to validate genetic variants.

Benefits of technology

Enhances the sensitivity and accuracy of detecting genetic variants by reducing noise and sequencing errors, allowing for more reliable cancer diagnosis and monitoring through increased diagnostic confidence indices.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007594522000002
    Figure 0007594522000002
  • Figure 0007594522000003
    Figure 0007594522000003
  • Figure 0007594522000004
    Figure 0007594522000004
Patent Text Reader

Abstract

Providing diagnostic methods. [Solution] A method for analyzing a subject's disease state includes characterizing the subject's genetic information at two or more time points or instances with a genetic analyzer, e.g., a deoxyribonucleic acid (DNA) sequencer, and using information from the two or more time points or instances to generate a test result adjusted for the characterization of the subject's genetic information. In some embodiments, the genetic data includes current sequence read data and prior sequence read data, and (c) includes comparing the current sequence read data with the prior sequence read data and accordingly updating a diagnostic confidence index for the characterization of the subject's genetic information, wherein the diagnostic confidence index represents a probability of identifying one or more genetic variations in the subject's biological sample.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] cross reference This invention claims the benefit of U.S. Provisional Application No. 62 / 155,755, filed May 1, 2015, which is incorporated herein by reference. [Background technology]

[0002] background Cancer is a major cause of disease worldwide. Tens of millions of people worldwide are diagnosed with cancer each year, and more than half of the patients will ultimately die from it. In many countries, cancer ranks as the second most common cause of death after cardiovascular disease.

[0003] Several screening tests are available to detect cancer. Physical examination and medical history look for general signs of health, including checking for signs of disease, such as lumps or other abnormal physical symptoms. A history of the patient's health habits and past illnesses and treatments is also taken. Laboratory tests are another type of screening test and may require a medical procedure to obtain a sample of body tissue, blood, urine or other substances before the laboratory test is performed. Imaging methods screen for cancer by producing a visual depiction of an area inside the body. Genetic tests detect certain harmful genetic mutations that have been associated with some types of cancer. Genetic tests are particularly useful for a number of diagnostic methods.

[0004] One approach for cancer screening can include monitoring samples derived from cell-free nucleic acid, which is a collection of polynucleotides that can be found in different types of body fluids.In some cases, disease can be characterized or detected based on the detection of genetic variation, such as the change in copy number variation and / or sequence variation of one or more nucleic acid sequences or the occurrence of other certain rare genetic changes.Cell-free DNA ("cfDNA") can contain genetic variation associated with certain diseases.With the improvement of nucleic acid sequencing and manipulation techniques, there is a need in the art for improved methods and systems for using cell-free DNA to detect and monitor disease. Summary of the Invention [Means for solving the problem]

[0005] In one aspect, the disclosure provides a method for analyzing a disease state of a subject, the method comprising: (a) generating genetic data from nucleic acid molecules in a biological sample of the subject obtained at (i) two or more time points or (ii) substantially the same time point using a genetic analyzer, wherein the genetic data relates to genetic information of the subject, and the biological sample comprises an acellular biological sample; (b) receiving the genetic data from the genetic analyzer; (c) generating, by one or more programmed computer processors, adjusted test results using the genetic data in characterizing the genetic information of the subject; and (d) outputting the adjusted test results to a computer memory.

[0006] In some embodiments, the genetic data comprises current sequence read data and prior sequence read data, and (c) comprises comparing the current sequence read data to the prior sequence read data and updating a diagnostic confidence index accordingly with respect to the characterization of the subject's genetic information, wherein the diagnostic confidence index represents a probability of identifying one or more genetic variations in the subject's biological sample.

[0007] In some embodiments, the method further comprises generating a confidence interval for the current sequence read data, hi some embodiments, the method further comprises comparing the confidence interval to one or more prior confidence intervals to determine disease progression based on overlapping confidence intervals.

[0008] In some embodiments, if the biological sample is obtained at two or more time points, including a first time point and a second time point, and information from the first time point corroborates information from the second time point, then (c) comprises increasing a diagnostic confidence index in a subsequent or prior characterization. In some embodiments, if the biological sample is obtained at two or more time points, including a first time point and a second time point, and information from the first time point corroborates information from the second time point, then (c) comprises increasing a diagnostic confidence index in a subsequent characterization.

[0009] In some embodiments, if a first covariate variation is detected in the genetic data and a second covariate variation is detected, (c) comprises increasing a diagnostic confidence index in subsequent characterization.

[0010] In some embodiments, the biological sample is obtained at two or more time points, including a first time point and a second time point, and if information from the first time point contradicts information from the second time point, (c) comprises reducing the diagnostic confidence index in subsequent characterization.

[0011] In some embodiments, the method further comprises obtaining a subsequent characterization and leaving the diagnostic confidence index intact in the subsequent characterization of the de novo information. In some embodiments, the method further comprises determining a frequency of one or more genetic variants detected in a set of sequence read data included in said genetic data, and generating an adjusted test result, at least in part, by comparing said frequency of said one or more genetic variants at two or more of said time points. In some embodiments, the method further comprises determining an amount of copy number variation copy number variation at one or more genetic loci detected in a set of sequence read data included in said genetic data, and generating an adjusted test result, at least in part, by comparing said amount at two or more of said time points. In some embodiments, the method further comprises using said adjusted test result to provide said subject with (i) a therapeutic intervention or (ii) a diagnosis of a health condition or disease.

[0012] In some embodiments, the genetic data comprises sequence data from genomic locations that contain disease-associated or cancer-associated genetic variants.

[0013] In some embodiments, the method further comprises using said adjusted test results to increase the sensitivity of detecting genetic variants by increasing the read depth of polynucleotides in a sample from said subject.

[0014] In some embodiments, the genetic data comprises a first set of genetic data and a second set of genetic data, the first set of genetic data being at or below a detection threshold and the second set of genetic data being above the detection threshold. In some embodiments, the detection threshold is a noise threshold. In some embodiments, the method further comprises (c) adjusting the subject's diagnosis from negative or indeterminate to positive when the same genetic variant is detected in the first set of genetic data and the second set of genetic data at multiple sampling instances or time points. In some embodiments, the method further comprises (c) adjusting the subject's diagnosis from negative or indeterminate to positive in characterization from the earlier time point when the same genetic variant is detected in the first set of genetic data at an earlier time point and the second set of genetic data at a later time point.

[0015] In some embodiments, the disease state is cancer and the genetic analyzer is a nucleic acid sequencer.

[0016] In some embodiments, the biological sample comprises at least two different types of biological samples. In some embodiments, the biological sample comprises the same type of biological sample. In some embodiments, the biological sample is a blood sample. In some embodiments, the nucleic acid molecule is cell-free deoxyribonucleic acid (DNA).

[0017] In another aspect, the disclosure provides a method of detecting trends in the amount of a cancer polynucleotide over time in a biological sample from a subject, the method comprising: using one or more programmed computer processors to determine a frequency of the cancer polynucleotide at each of a plurality of time points; determining an error range for the frequency at each of the plurality of time points to provide at least a first error range at a first time point and a second error range at a second time point after the first time point; and (1) determining whether the first error range overlaps with the second error range, wherein the overlap indicates stability of the frequency of the cancer polynucleotide at the plurality of time points, (2) determining whether the second error range is greater than the first error range and thus represents an increase in the frequency of the cancer polynucleotide at the plurality of time points, or (3) determining whether the second error range is less than the first error range and thus represents a decrease in the frequency of the cancer polynucleotide at the plurality of time points.

[0018] In some embodiments, the cancer polynucleotide is a deoxyribonucleic acid (DNA) molecule. In some embodiments, the DNA is cell-free DNA.

[0019] In some embodiments, the frequency at each of the multiple time points is determined by sequencing the nucleic acid molecule in the subject's biological sample. In some embodiments, the biological sample is a blood sample. In some embodiments, the nucleic acid molecule is cell-free deoxyribonucleic acid (DNA).

[0020] In another aspect, the disclosure provides a method of detecting one or more genetic variations and / or an amount of genetic variations in a subject, comprising: sequencing nucleic acid molecules in a cell-free nucleic acid sample of the subject by a genetic analyzer to generate a first set of sequence read data at a first time point; comparing said first set of sequence read data with at least a second set of sequence read data obtained at at least a second time point prior to said first time point to provide a comparison of the first set of sequence read data and said at least a second set of sequence read data; using said comparison and updating a diagnostic confidence index accordingly, said diagnostic confidence index representing a probability of identifying one or more genetic variations in the cell-free nucleic acid sample of the subject; and detecting the presence or absence of said one or more genetic variations and / or the amount of genetic variations in nucleic acid molecules in the cell-free nucleic acid sample of the subject based on said diagnostic confidence index.

[0021] In some embodiments, the method further comprises obtaining the cell-free nucleic acid molecule from said subject.

[0022] In some embodiments, the method further comprises sequencing additional cell-free nucleic acid molecules of the subject to generate a third set of sequence read data at a third time point after the first time point, and detecting the presence or absence of one or more genetic variations and / or the amount of genetic variations in the additional cell-free nucleic acid molecules of the subject based on the diagnostic confidence index.

[0023] In some embodiments, the method further comprises increasing the diagnostic confidence index if information obtained from the first set of sequence read data at the first time point corroborates information obtained from the at least a second set of sequence read data at the second time point.

[0024] In some embodiments, the method further comprises decreasing the diagnostic confidence index if information obtained from the first set of sequence reads at the first time point does not corroborate or contradicts information obtained from the at least a second set of sequence reads at the second time point, hi some embodiments, the method further comprises leaving the diagnostic confidence index unchanged upon subsequent characterization of the de novo information.

[0025] In another aspect, the disclosure provides a method for detecting mutations in a cell-free nucleic acid sample of a subject, the method comprising: (a) determining consensus sequences by comparing current sequence read data obtained from a genetic analyzer with prior sequence read data from a prior time to provide a comparison, and updating a diagnostic confidence index based on said comparison, wherein each consensus sequence corresponds to a unique polynucleotide in a set of tagged parent polynucleotides derived from said cell-free nucleic acid sample; and (b) generating a genetic profile of extracellular polynucleotides in said subject based on the diagnostic confidence, wherein said genetic profile comprises data resulting from copy number variation or mutation analysis.

[0026] In some embodiments, the method further comprises, prior to (a), providing a plurality of sets of tagged parent polynucleotides derived from the cell-free nucleic acid sample, each set mappable to a different reference sequence.

[0027] In some embodiments, the method further comprises normalizing the ratio of variance or frequency for each mappable base position using the consensus sequence to determine actual or potential rare variant(s) or mutation(s); and comparing the resulting counts for each region with potential rare variant(s) or mutation(s) to counts similarly derived from a reference sample.

[0028] In another aspect, the disclosure provides a method of detecting aberrant cellular activity comprising: providing at least one set of tagged parent polynucleotides derived from a biological sample of a subject; amplifying the tagged parent polynucleotides in the set to generate a corresponding set of amplified progeny polynucleotides; sequencing a subset of the set of amplified progeny polynucleotides using a genetic analyzer to generate a set of sequencing read data; and collapsing the set of sequencing read data to generate a set of consensus sequences by comparing current sequence read data with prior sequence read data from at least one prior time and updating a diagnostic confidence index accordingly, wherein the diagnostic confidence index represents a probability of identifying one or more genetic variations in the biological sample of the subject, and each consensus sequence corresponds to a unique polynucleotide in the set of tagged parent polynucleotides.

[0029] In some embodiments, the method further comprises increasing the diagnostic confidence index if the set of sequencing read data is identified at least one of the prior times. In some embodiments, the method further comprises decreasing the diagnostic confidence index if the set of sequencing read data is not identified at least one of the prior times. In some embodiments, the method further comprises leaving the diagnostic confidence index unchanged if the set of sequencing read data is identified at least one of the prior times but is inconclusive.

[0030] In some embodiments, the set of sequencing reads comprises at least one sequencing read.

[0031] In some embodiments, the biological sample is a blood sample. In some embodiments, the biological sample comprises cell-free nucleic acid molecules, and at least one set of tagged parent polynucleotides is generated from the cell-free nucleic acid molecules.

[0032] In some embodiments, the method further comprises generating a genetic profile of the polynucleotide of the subject, the genetic profile comprising an analysis of one or more genetic variants of the subject. In some embodiments, the polynucleotide comprises an extracellular polynucleotide.

[0033] In another aspect, the disclosure provides a method for detecting mutations in a cell-free or substantially cell-free sample of a subject, the method comprising: (a) sequencing extracellular polynucleotides from a body sample of the subject with a genetic analyzer; (b) generating a plurality of sequencing reads for each of the extracellular polynucleotides; (c) filtering out reads that do not meet a set threshold; (d) mapping sequence reads derived from the sequencing to a reference sequence; (e) identifying a subset of mapped sequence reads that align with variants of the reference sequence at each mappable base position; (f) calculating, for each mappable base position, a ratio of (i) the number of mapped sequence reads that contain a variant compared to the reference sequence to (ii) the total number of sequence reads at each mappable base position; and (g) comparing the sequence reads to other sequence reads from at least one previous time point using one or more programmed computer processors and updating a diagnostic confidence index accordingly, wherein the diagnostic confidence index represents a probability of identifying the variant.

[0034] In some embodiments, the body sample is a blood sample. In some embodiments, the extracellular polynucleotides comprise cell-free deoxyribonucleic acid (DNA) molecules.

[0035] In another aspect, the disclosure provides a method for operating a genetic testing apparatus, comprising the steps of: providing initial starting genetic material obtained from a body sample obtained from a subject; converting double-stranded polynucleotide molecules from said initial starting genetic material into at least one set of non-specifically tagged parent polynucleotides, each polynucleotide in a set being mappable to a reference sequence; and for each set of tagged parent polynucleotides: (i) amplifying said tagged parent polynucleotides in said set to generate a corresponding set of amplified progeny polynucleotides; (ii) sequencing said set of amplified progeny polynucleotides to generate a set of sequencing read data; and (iii) collapsing said set of sequencing read data to generate a set of consensus sequences. (iv) analyzing the set of consensus sequences for each set of tagged parent molecules; (v) comparing current sequence read data with prior sequence read data from at least one other time point; and (vi) updating a diagnostic confidence index accordingly, wherein the diagnostic confidence index represents a probability of identifying one or more genetic variations in the subject's body sample.

[0036] In some embodiments, the body sample is a blood sample.In some embodiments, the initial starting genetic material comprises cell-free deoxyribonucleic acid (DNA).

[0037] In some embodiments, the set of consensus sequences for each set of tagged parent molecules is analyzed separately.

[0038] In some embodiments, analyzing comprises detecting mutations, indels, copy number variations, transversions, translocations, inversions, deletions, aneuploidy, partial aneuploidy, polyploidy, chromosomal instability, chromosomal structural alterations, gene fusions, chromosomal fusions, gene truncations, gene amplifications, gene duplications, chromosomal damage, DNA damage, abnormal changes in nucleic acid chemical modifications, abnormal changes in epigenetic patterns, abnormal changes in nucleic acid methylation, infections, or cancer.

[0039] In some embodiments, (vi) comprises increasing a diagnostic confidence index for the current sequence read data if information from the prior sequence read data corroborates information from the current sequence read data. In some embodiments, (vi) comprises decreasing a diagnostic confidence index for the current sequence read data if information from the prior sequence read data contradicts information from the current sequence read data. In some embodiments, (vi) comprises keeping a diagnostic confidence index for the current sequence read data the same if information from the prior sequence read data is inconclusive with respect to information from the current sequence read data.

[0040] In some embodiments, (v) comprises comparing variations in the one or more current sequence reads to variations in the one or more prior sequence reads.

[0041] In another aspect, the disclosure provides a method for detecting one or more genetic variants in a subject, the method comprising: (a) obtaining nucleic acid molecules from one or more acellular biological samples of the subject; (b) assaying the nucleic acid molecules to generate a first set of genetic data and a second set of genetic data, wherein the first set of genetic data and / or the second set of genetic data is within a detection threshold; (c) comparing the first set of genetic data to the second set of genetic data to identify the one or more genetic variants in the first set of genetic data or the second set of genetic data; and (d) updating, using one or more programmed computer processors, a diagnostic confidence index for identifying the one or more genetic variants in the acellular biological sample of the subject based on the one or more genetic variants identified in (c).

[0042] In some embodiments, the first set of genetic data and the second set of genetic data are within the detection threshold. In some embodiments, the first set of genetic data is within the detection threshold and the second set of genetic data is above the detection threshold. In some embodiments, the detection threshold is a noise threshold.

[0043] In some embodiments, the method further comprises identifying said one or more genetic variants in said first set of genetic data and increasing said diagnostic confidence index.

[0044] In some embodiments, the subsets of nucleic acid molecules are assayed at different time points. In some embodiments, the nucleic acid molecules are obtained from multiple cell-free biological samples at the same or different time points.

[0045] In some embodiments, the nucleic acid molecule is cell-free deoxyribonucleic acid (DNA). In some embodiments, the DNA is cell-free DNA (cfDNA).

[0046] In some embodiments, the method further comprises generating a genetic profile of the subject, said genetic profile comprising said diagnostic confidence index for identifying said one or more genetic variants.

[0047] In some embodiments, a covariate variant is identified in the first set of genetic data in (c), and the method further comprises updating the diagnostic confidence index with respect to identifying a second covariate variant in the cell-free biological sample of the subject. In some embodiments, the method further comprises increasing the diagnostic confidence index in (c) if the first set of genetic data is observed in the second set of genetic data. In some embodiments, the method further comprises decreasing the diagnostic confidence index in (c) if the first set of genetic data differs from the second set of genetic data.

[0048] In some embodiments, the detection threshold includes errors introduced by sequencing or amplification.

[0049] In some embodiments, the detection threshold comprises an error rate per base of 0.5% to 5%. In some embodiments, the detection threshold comprises an error rate per base of 0.5% to 1%.

[0050] In some embodiments, the nucleic acid molecule is obtained from a second cell-free biological sample of the subject. In some embodiments, the second cell-free biological sample is obtained after obtaining the cell-free biological sample of (a). In some embodiments, the second cell-free biological sample is obtained prior to obtaining the cell-free biological sample of (a). In some embodiments, the second cell-free biological sample is obtained simultaneously with obtaining the cell-free biological sample of (a). In some embodiments, the first set of genetic data corresponds to the cell-free biological sample of (a) and the second set of genetic data corresponds to the second cell-free biological sample.

[0051] In some embodiments, the method further comprises attaching a tag to the nucleic acid molecule to generate tagged parent polynucleotides; amplifying the tagged parent polynucleotides to generate tagged progeny polynucleotides; and sequencing the tagged progeny polynucleotides to generate sequencing read data.

[0052] In some embodiments, the attaching step comprises uniquely tagging the nucleic acid molecules, hi some embodiments, the attaching step comprises non-uniquely tagging the nucleic acid molecules such that 5% or less of the nucleic acid molecules are uniquely tagged.

[0053] In some embodiments, the method further comprises selectively enriching for sequences of interest prior to sequencing.

[0054] In some embodiments, the method further comprises grouping the sequence reads into families based at least on sequence tags, in some embodiments, grouping the sequence reads is further based on one or more of the following: sequence information at the beginning of a sequence read derived from a nucleic acid molecule, sequence information at the end of the sequence derived from a nucleic acid molecule, and a length of the sequence read.

[0055] In some embodiments, the method further comprises comparing the sequence read data grouped within each family to determine a consensus sequence in each family, where each consensus sequence corresponds to a unique polynucleotide among the tagged parent polynucleotides.

[0056] In some embodiments, the method further comprises obtaining less than 100 ng of the nucleic acid molecule.

[0057] In another aspect, the disclosure provides a method for calling genetic variants in cell-free deoxyribose nucleic acid (cfDNA) from a subject, the method comprising: (a) sequencing cfDNA from a sample taken from the subject at a first time point using a DNA sequencing system; (b) detecting a genetic variant in the sequenced cfDNA from the first time point, wherein the genetic variant is detected at a level below the diagnostic limit; (c) sequencing cfDNA from a sample taken from the subject at one or more subsequent time points using the DNA sequencing system; (d) detecting the genetic variant in the sequenced cfDNA from the one or more subsequent time points, wherein the genetic variant is detected at a level below the diagnostic limit; and (e) calling the sample as positive for the genetic variant based on detecting the genetic variant below the diagnostic limit in samples taken at multiple time points.

[0058] In some embodiments, the method further includes (f) detecting a trend, where at a first time point the genetic variant is detected below the diagnostic limit and called positive, and at one or more subsequent time points the genetic variant is detected above the diagnostic limit, thereby increasing the genetic variant.

[0059] In some embodiments, the diagnostic limit is about 1.0% or less.

[0060] In another aspect, the disclosure provides a method for calling genetic variants in cell-free deoxyribose nucleic acid (cfDNA) from a subject, the method comprising: (a) sequencing cfDNA from a sample from the subject using a deoxyribonucleic acid (DNA) sequencing system; (b) detecting a genetic variant in the sequenced cfDNA, wherein the genetic variant is detected at a level below the diagnostic limit; (c) sequencing cfDNA from the sample taken from the subject using the DNA sequencing system, wherein the sample is resequenced one or more times; (d) detecting the genetic variant in the sequenced cfDNA from one or more resequenced samples, wherein the genetic variant is detected at a level below the diagnostic limit; and (e) calling the sample as positive for the genetic variant based on detecting the genetic variant in the resequenced sample below the diagnostic limit.

[0061] In another aspect, the present disclosure provides a non-transitory computer-readable medium comprising machine-executable code that, upon execution on one or more computer processors, performs any of the methods described above or elsewhere herein.

[0062] In another aspect, the present disclosure provides a computer system including one or more computer processors and a memory coupled thereto, the memory including a non-transitory computer readable medium including machine executable code that, upon execution on the one or more computer processors, performs any of the methods described above or elsewhere herein.

[0063] Additional aspects and advantages of the present disclosure will become readily apparent to those skilled in the art from the following detailed description, in which only illustrative embodiments of the present disclosure are shown and described. As will be understood, the present disclosure is capable of other and different embodiments, and its several details are capable of modifications in various obvious respects, all without departing from the present disclosure. Accordingly, the drawings and description should be regarded as illustrative in nature, and not as restrictive. Incorporation by Reference

[0064] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.

[0065] The novel features of the present disclosure are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present disclosure will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the disclosure are utilized, and the accompanying drawings of which: In an embodiment of the present invention, for example, the following items are provided: (Item 1) 1. A method for analyzing a disease state in a subject, comprising: (a) generating genetic data from nucleic acid molecules in a biological sample of said subject obtained using a genetic analyzer at (i) two or more time points or (ii) substantially the same time point, said genetic data relating to genetic information of said subject, said biological sample comprising a cell-free biological sample; (b) receiving the genetic data from the genetic analyzer; (c) generating, by one or more programmed computer processors, adjusted test results using the genetic data in characterizing the genetic information of the subject; (d) outputting the adjusted test results to a computer memory; The method includes: (Item 2) 2. The method of claim 1, wherein the genetic data comprises current sequence read data and prior sequence read data, and (c) comprises comparing the current sequence read data to the prior sequence read data and updating a diagnostic confidence index accordingly with respect to the characterization of the subject's genetic information, wherein the diagnostic confidence index represents a probability of identifying one or more genetic variations in the subject's biological sample. (Item 3) 3. The method of claim 2, further comprising generating a confidence interval for the current sequence read data. (Item 4) 4. The method of claim 3, further comprising comparing the confidence interval to one or more prior confidence intervals to determine disease progression based on overlapping confidence intervals. (Item 5) 2. The method of claim 1, wherein the biological sample is obtained at two or more time points, including a first time point and a second time point, and if information from the first time point corroborates information from the second time point, (c) comprises increasing a diagnostic confidence index in a subsequent or previous characterization. (Item 6) 2. The method of claim 1, wherein the biological sample is obtained at two or more time points, including a first time point and a second time point, and if information from the first time point corroborates information from the second time point, (c) comprises increasing a diagnostic confidence index in subsequent characterization. (Item 7) 2. The method of claim 1, wherein if a first covariate variation is detected in the genetic data and a second covariate variation is detected, (c) comprises increasing a diagnostic confidence index in subsequent characterization. (Item 8) 2. The method of claim 1, wherein the biological sample is obtained at two or more time points, including a first time point and a second time point, and if information from the first time point contradicts information from the second time point, (c) comprises reducing the diagnostic confidence index in subsequent characterization. (Item 9) 2. The method of claim 1, further comprising obtaining a subsequent characterization and leaving the diagnostic confidence index intact on the subsequent characterization of the de novo information. (Item 10) 2. The method of claim 1, further comprising determining a frequency of one or more genetic variants detected in a set of sequence read data included in said genetic data, and generating said adjusted test result, at least in part, by comparing said frequencies of said one or more genetic variants at two or more of said time points. (Item 11) 2. The method of claim 1, further comprising determining an amount of copy number variation at one or more genetic loci detected in a set of sequence read data included in said genetic data, and generating an adjusted test result, at least in part, by comparing said amounts at two or more said time points. (Item 12) 2. The method of claim 1, further comprising using the adjusted test results to provide to the subject (i) a therapeutic intervention or (ii) a diagnosis of a condition or disease. (Item 13) 2. The method of claim 1, wherein the genetic data comprises sequence data from genomic locations that contain disease-associated or cancer-associated genetic variants. (Item 14) 2. The method of claim 1, further comprising using the adjusted test result to increase the sensitivity of detecting genetic variants by increasing the read depth of polynucleotides in a sample from the subject. (Item 15) 2. The method of claim 1, wherein the genetic data comprises a first set of genetic data and a second set of genetic data, the first set of genetic data being at or below a detection threshold and the second set of genetic data being above the detection threshold. (Item 16) 16. The method of claim 15, wherein the detection threshold is a noise threshold. (Item 17) 16. The method of claim 15, further comprising adjusting the subject's diagnosis from negative or indeterminate to positive in (c) if the same genetic variant is detected in the first set of genetic data and the second set of genetic data at multiple sampling instances or time points. (Item 18) 16. The method of claim 15, further comprising adjusting the subject's diagnosis in characterization from the earlier time point from negative or indeterminate to positive in (c) if the same genetic variant is detected in the first set of genetic data at the earlier time point and the second set of genetic data at the later time point. (Item 19) 2. The method of claim 1, wherein the disease state is cancer and the genetic analyzer is a nucleic acid sequencer. (Item 20) 2. The method of claim 1, wherein the biological sample comprises at least two different types of biological sample. (Item 21) 2. The method of claim 1, wherein the biological samples comprise biological samples of the same type. (Item 22) 22. The method of claim 21, wherein the biological sample is a blood sample. (Item 23) 23. The method of claim 22, wherein the nucleic acid molecule is cell-free deoxyribonucleic acid (DNA). (Item 24) 1. A method for detecting trends in amounts of cancer polynucleotides over time in a biological sample from a subject, comprising: determining, using one or more programmed computer processors, a frequency of said cancer polynucleotides at each of a plurality of time points; determining an error range for the frequency at each of the plurality of time points to provide at least a first error range at a first time point and a second error range at a second time point after the first time point; (1) determining whether the first error range overlaps with the second error range, the overlap indicating stability in frequency of the cancer polynucleotide at the multiple time points; (2) determining whether the second error range is greater than the first error range, thus representing an increase in frequency of the cancer polynucleotide at the multiple time points; or (3) determining whether the second error range is less than the first error range, thus representing a decrease in frequency of the cancer polynucleotide at the multiple time points. The method includes: (Item 25) 25. The method of item 24, wherein the DNA is cell-free DNA. (Item 26) 1. A method for detecting one or more genetic variations and / or the amount of genetic variations in a subject, comprising: sequencing nucleic acid molecules in the cell-free nucleic acid sample of the subject with a genetic analyzer to generate a first set of sequence read data at a first time point; comparing said first set of sequence read data to at least a second set of sequence read data obtained at at least a second time point prior to said first time point to provide a comparison of the first set of sequence read data and said at least second set of sequence read data; using said comparison and updating a diagnostic confidence index accordingly, said diagnostic confidence index representing a probability of identifying one or more genetic variations in a cell-free nucleic acid sample of said subject; detecting the presence or absence and / or amount of said one or more genetic variations in a nucleic acid molecule in a cell-free nucleic acid sample of said subject based on said diagnostic confidence index; The method includes: (Item 27) 27. The method of claim 26, further comprising obtaining a cell-free nucleic acid molecule from the subject. (Item 28) 27. The method of claim 26, further comprising: (i) increasing the diagnostic confidence index if information obtained from the first set of sequence read data at the first time point corroborates information obtained from the at least second set of sequence read data at the second time point; (ii) decreasing the diagnostic confidence index if information obtained from the first set of sequence read data at the first time point does not corroborate or contradicts information obtained from the at least second set of sequence read data at the second time point; or (iii) leaving the diagnostic confidence index unchanged upon subsequent characterization of de novo information. (Item 29) 1. A method for detecting mutations in a cell-free nucleic acid sample from a subject, comprising: (a) determining consensus sequences by comparing current sequence read data from a genetic analyzer with prior sequence read data from a prior time to provide a comparison, and updating a diagnostic confidence index based on said comparison, wherein each consensus sequence corresponds to a unique polynucleotide in a set of tagged parent polynucleotides derived from said cell-free nucleic acid sample; (b) generating a genetic profile of extracellular polynucleotides in the subject based on a diagnostic confidence level, the genetic profile including data resulting from copy number variation or mutation analysis; The method includes: (Item 30) normalizing the ratio of variance or frequency for each mappable base position using the consensus sequence to determine actual or potential rare variant(s) or mutation(s); and Comparing the resulting counts for each region with potential rare variant(s) or mutation(s) to similarly derived counts from a reference sample. 30. The method of claim 29, further comprising: (Item 31) 1. A method for detecting abnormal cellular activity, comprising: providing at least one set of tagged parent polynucleotides derived from a biological sample of a subject; amplifying the tagged parent polynucleotides in the set to generate a corresponding set of amplified progeny polynucleotides; sequencing a subset of said set of amplified progeny polynucleotides using a genetic analyzer to generate a set of sequencing read data; collapsing the set of sequencing read data to generate a set of consensus sequences by comparing current sequence read data with prior sequence read data from at least one prior time and updating a diagnostic confidence index accordingly, the diagnostic confidence index representing a probability of identifying one or more genetic variations in the subject's biological sample, each consensus sequence corresponding to a unique polynucleotide in the set of tagged parent polynucleotides; The method includes: (Item 32) 32. The method of claim 31, further comprising the steps of: (i) increasing the diagnostic confidence index if the set of sequencing read data is identified at least one of the prior epochs; (ii) decreasing the diagnostic confidence index if the set of sequencing read data is not identified at least one of the prior epochs; or (iii) leaving the diagnostic confidence index unchanged if the set of sequencing read data is identified at least one of the prior epochs but is inconclusive. (Item 33) 1. A method for detecting mutations in a cell-free or substantially cell-free sample from a subject, comprising: (a) sequencing extracellular polynucleotides from a body sample of said subject with a genetic analyzer; (b) generating a plurality of sequencing reads for each of said extracellular polynucleotides; (c) filtering out read data that does not meet a set threshold; (d) mapping sequence reads derived from said sequencing to a reference sequence; (e) identifying a subset of mapped sequence reads that align with a variant of the reference sequence at each mappable base position; (f) calculating, for each mappable base position, a ratio of (i) the number of mapped sequence reads that contain a variant compared to the reference sequence, to (ii) the total number of sequence reads at each mappable base position; (g) comparing said sequence reads with other sequence reads from at least one previous time point using one or more programmed computer processors and updating a diagnostic confidence index accordingly, said diagnostic confidence index representing a probability of identifying said variant; The method includes: (Item 34) 34. The method of claim 33, wherein the extracellular polynucleotide comprises a cell-free deoxyribonucleic acid (DNA) molecule. (Item 35) 1. A method for operating a genetic testing device, comprising: providing initial starting genetic material obtained from a body sample obtained from a subject; converting double-stranded polynucleotide molecules from said initial starting genetic material into at least one set of non-specifically tagged parent polynucleotides, each polynucleotide in the set being mappable to a reference sequence; and For each set of tagged parent polynucleotides: (i) amplifying the tagged parent polynucleotides in the set to generate a corresponding set of amplified progeny polynucleotides; (ii) sequencing said set of amplified progeny polynucleotides to generate a set of sequencing read data; (iii) collapsing the set of sequencing reads to generate a set of consensus sequences, the collapsing using sequence information from the tags and at least one of (1) sequence information at a beginning region of the sequence reads, (2) sequence information at an end region of the sequence reads, and (3) a length of the sequence reads, each consensus sequence of the set of consensus sequences corresponding to a polynucleotide molecule in the set of tagged parent polynucleotides; and (iv) analyzing said set of consensus sequences for each set of tagged parent molecules; (v) comparing the current sequence read data to prior sequence read data from at least one other time point; and (vi) updating a diagnostic confidence index accordingly, said diagnostic confidence index representing the probability of identifying one or more genetic variations in said subject's body sample. The method includes: (Item 36) 36. The method of claim 35, wherein the initial starting genetic material comprises cell-free deoxyribonucleic acid (DNA). (Item 37) 36. The method of claim 35, wherein the set of consensus sequences for each set of tagged parent molecules is analyzed separately. (Item 38) 36. The method of claim 35, wherein (vi) comprises: (1) increasing a diagnostic confidence index of the current sequence read data if information from the prior sequence read data reinforces information from the current sequence read data; (2) decreasing a diagnostic confidence index of the current sequence read data if information from the prior sequence read data contradicts information from the current sequence read data; or (3) keeping a diagnostic confidence index of the current sequence read data the same if information from the prior sequence read data is inconclusive with respect to information from the current sequence read data. (Item 39) 36. The method of claim 35, wherein (v) comprises comparing variations in the one or more current sequence reads to variations in the one or more prior sequence reads. (Item 40) 1. A method for detecting one or more genetic variants in a subject, comprising: (a) obtaining nucleic acid molecules from one or more acellular biological samples of said subject; (b) assaying the nucleic acid molecules to generate a first set of genetic data and a second set of genetic data, wherein the first set of genetic data and / or the second set of genetic data are within a detection threshold; (c) comparing the first set of genetic data to the second set of genetic data to identify the one or more genetic variants in the first set of genetic data or the second set of genetic data; (d) updating, using one or more programmed computer processors, a diagnostic confidence index for identifying the one or more genetic variants in the acellular biological sample of the subject based on the one or more genetic variants identified in (c); The method includes: (Item 41) 41. The method of claim 40, wherein the first set of genetic data and the second set of genetic data are within the detection threshold. (Item 42) 41. The method of claim 40, wherein the first set of genetic data is within the detection threshold and the second set of genetic data is above the detection threshold. (Item 43) 41. The method of claim 40, wherein the detection threshold is a noise threshold. (Item 44) 44. The method of claim 43, further comprising identifying the one or more genetic variants in the first set of genetic data and increasing the diagnostic confidence index. (Item 45) 41. The method of claim 40, wherein subsets of the nucleic acid molecules are assayed at different time points. (Item 46) 41. The method of item 40, wherein the nucleic acid molecules are obtained from multiple acellular biological samples at the same or different time points. (Item 47) 41. The method of claim 40, wherein the nucleic acid molecule is a cell-free deoxyribonucleic acid. (Item 48) 41. The method of claim 40, further comprising updating the diagnostic confidence index with respect to identifying a second covariate variant in a cell-free biological sample of the subject, wherein a covariate variant is identified in the first set of genetic data of (c). (Item 49) 41. The method of claim 40, further comprising: (1) increasing the diagnostic confidence index in (c) if the first set of genetic data is observed in the second set of genetic data; or (2) decreasing the diagnostic confidence index in (c) if the first set of genetic data differs from the second set of genetic data. (Item 50) 41. The method of claim 40, wherein the detection threshold comprises an error rate per base of 0.5% to 5%. (Item 51) 41. The method of claim 40, wherein the first set of genetic data corresponds to the acellular biological sample of (a) and the second set of genetic data corresponds to a second acellular biological sample. (Item 52) 1. A method for calling genetic variants in cell-free deoxyribose nucleic acid (cfDNA) from a subject, comprising: (a) sequencing cfDNA from a sample taken from a subject at a first time point using a DNA sequencing system; (b) detecting a genetic variant in the sequenced cfDNA from the first time point, wherein the genetic variant is detected at a level below the diagnostic limit; and (c) sequencing cfDNA from samples taken from the subject at one or more subsequent time points using the DNA sequencing system; (d) detecting said genetic variant in sequenced cfDNA from said one or more subsequent time points, wherein said genetic variant is detected at a level below said diagnostic limit; (e) calling the sample as positive for the genetic variant based on detecting the genetic variant below the diagnostic limit in samples taken at multiple time points; The method includes: (Item 53) 1. A method for calling genetic variants in cell-free deoxyribose nucleic acid (cfDNA) from a subject, comprising: (a) sequencing cfDNA from a sample from a subject using a deoxyribonucleic acid (DNA) sequencing system; (b) detecting genetic variants in the sequenced cfDNA, wherein the genetic variants are detected at levels below the diagnostic limit; (c) sequencing cfDNA from the sample taken from the subject using the DNA sequencing system, wherein the sample is resequenced one or more times; (d) detecting said genetic variants in sequenced cfDNA from one or more resequenced samples, wherein said genetic variants are detected at a level below the diagnostic limit; (e) calling the sample positive for the genetic variant based on detecting the genetic variant below the diagnostic limit in the resequenced sample; Methods including: (Item 54) 1. A method for detecting one or more genetic variants in a subject, comprising: (a) obtaining nucleic acid molecules from one or more acellular biological samples of said subject; (b) assaying the nucleic acid molecule to generate a set of genetic data, wherein a genetic variant is within a detection threshold in the set of genetic data; (c) identifying one or more covariate genetic variations associated with said genetic variations by querying said set of genetic data for one or more covariate genetic variations associated with said genetic variations, within a detection threshold; (d) updating, using one or more programmed computer processors, a diagnostic confidence index for identifying the one or more genetic variants in the acellular biological sample of the subject based on the one or more genetic variants identified in (c); The method includes: (Item 55) 1. A method for processing genetic data, comprising: (a) receiving genetic data generated from a cell-free nucleic acid sample of a subject from a genetic analyzer; (b) analyzing the genetic data using a programmed computer processor to identify one or more genetic variants within the genetic data; (c) providing an output to an electronic portal corresponding to the one or more genetic variants identified in (b); The method includes: (Item 56) Item 56. The method of item 55, wherein the one or more results are output in a web portal or graphical user interface. (Item 57) (a) sequencing cfDNA from a subject using a genetic sequencing system to generate sequencing data; (b) receiving the sequence data into a computer memory; (c) using the processor to execute logic: (i) determining gene variant frequencies at one or more loci; (ii) determining whether the frequency of the genetic variant is above or below a predefined diagnostic limit; (iii) calling the genetic variant as present in the sample if the frequency is above the diagnostic limit; (iv) or, if the frequency is below the diagnostic limit, accessing sequence dates from the subject taken at other times and calling the genetic variant as present if the variant is detected at the other time; (v) generating a report identifying the genetic variants that were called present; Steps and; (d) sending said report to a website where said report can be viewed in a graphical user interface; The method includes: [Brief description of the drawings]

[0066] [Figure 1A] 1A-1D illustrate an exemplary system for reducing error rates and bias in DNA sequence reads. [Figure 1B] 1A-1D illustrate an exemplary system for reducing error rates and bias in DNA sequence reads. [Figure 1C] 1A-1D illustrate an exemplary system for reducing error rates and bias in DNA sequence reads. [Figure 1D] 1A-1D illustrate an exemplary system for reducing error rates and bias in DNA sequence reads.

[0067] [Diagram 2] FIG. 2 illustrates an exemplary process for analyzing polynucleotides in a sample of initial genetic material.

[0068] [Diagram 3] FIG. 3 illustrates another exemplary process for analyzing polynucleotides in a sample of initial genetic material.

[0069] [Figure 4]FIG. 4 illustrates another exemplary process for analyzing polynucleotides in a sample of initial genetic material.

[0070] [Figure 5A] 5A and 5B show schematics of internet accessible access to reports generated from copy number variation analysis of subjects with cancer. [Figure 5B] 5A and 5B show schematics of internet accessible access to reports generated from copy number variation analysis of subjects with cancer.

[0071] [Figure 6] FIG. 6 shows a schematic diagram of internet-enabled access to reports of subjects with cancer.

[0072] [Figure 7] FIG. 7 illustrates a computer system programmed or otherwise configured to analyze genetic data.

[0073] [Figure 8] FIG. 8 shows detection of sequences in samples contaminated with nucleic acids harboring cancer mutations.

[0074] [Figure 9] FIG. 9 shows a gene panel that can be used with the methods and systems of the present disclosure. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0075] Detailed Description While various embodiments of the present invention have been shown and described herein, it will be apparent to those skilled in the art that such embodiments are provided by way of example only. Numerous modifications, changes and substitutions may occur to those skilled in the art without departing from the present invention. It should be understood that various alternatives to the embodiments of the present invention described herein may be used.

[0076] The terms used herein are for the purpose of describing particular embodiments only and are not intended to be limiting of the present invention. As used herein, the singular forms "a," "an," and "the" are intended to include the plural forms unless the context clearly dictates otherwise. Furthermore, to the extent the terms "including," "including," "has," "with," or variants thereof are used in the detailed description and / or claims, such terms are intended to be as inclusive as the term "comprising."

[0077] The term "about" or "approximately" means within an acceptable error range of a particular value as determined by one of ordinary skill in the art, which depends in part on how the value is measured or determined, i.e., the limitations of the measurement system. For example, "about" can mean within 1 or more than 1 standard deviation, as is customary in the art. Alternatively, "about" can mean within a range of up to 20%, up to 10%, up to 5%, or up to 1% of a given value. Alternatively, particularly with respect to biological systems or processes, the term can mean within an order of magnitude of a value, e.g., within 5-fold or within 2-fold. When a particular value is described in this application and claims, the term "about" should be assumed to mean within an acceptable error range of the particular value, unless otherwise specified.

[0078] In certain embodiments, diagnosis involves detecting (e.g., measuring) a signal that represents a disease, such as a biomarker, and correlating the detection or measurement with a disease state. However, the signal may be weak due to low sample concentration, or it may be masked by noise. If the signal is weak and is at or below the noise threshold or detection limit, it may be difficult to distinguish the signal generated by the detection system from noise, or to detect the signal itself. In such cases, the diagnosis may not be made with confidence. Diagnostic confidence can be enhanced by looking at genetic data or detected variations from multiple time points, multiple tests, or multiple commonly detected covariate genetic variants as confirmatory signals.

[0079] As used herein, the terms detection limit and diagnostic limit generally refer to the ability to detect the presence or absence or amount of a given gene or variant with a certain confidence level. As generally used herein, detection threshold refers to the range at or below the detection limit where a certain gene variant is undetectable or cannot be distinguished from noise. In some cases, "detection limit" may be the lowest frequency or concentration at which a variant is detected 95% of the time in a variant positive sample. Diagnostic limit may be the lowest frequency that can be called positive. Diagnostic limit may be about 0.01% to about 1%. Diagnostic limit may be about 5% or less, about 1.0%, about 0.8%, about 0.5%, about 0.25%, about 0.1%, about 0.08%, about 0.05%, about 0.03%, about 0.01% or less. In some cases, detection limit may be the same as diagnostic limit. Detection limit or diagnostic limit may be noise limit or noise threshold. In such a scenario, the detection limit or diagnostic limit is the limit at which signal cannot be distinguished from noise.

[0080] In some cases, the diagnostic limit may be lower than the detection limit. Using the methods and systems described herein, even when the genetic variant(s) are present at or below the detection limit, the genetic variant(s) present at or below the detection limit can be called positive with a predetermined confidence level (e.g., at least 80%, 90% or 95% confidence).

[0081] Thus, for example, sequence analysis of a sample can reveal several different gene variants and various frequencies or concentrations in the sample. The diagnostic limit can be set by the clinician, for example at 1%, i.e., no variant will be reported as "present" in the sample or "called" in the report unless the variant is present at a concentration of at least 1%. If a first variant is detected at 5%, the variant is "called" and reported as present in the sample. Another variant is detected at 0.5%. This is below the diagnostic limit and may be below the detection limit of the sequencing system. In this case, the clinician has several options. First, the same sample can be retested. If the variant is again detected below or above the detection limit, it is now "called" as present in the sample. Second, the sequence data can be examined for the presence of covariate variations. For example, the variant may be a known resistance mutation. If a driver mutation is detected in the same gene from the sequence data, this represents that the resistance mutant is likely not a "noise" detection and can again be called positive. Third, the subject can be tested again at a later time point. If the variant is detected in the later sample, the first sample can be called "present" for the variant. Alternatively, if the later test shows an amount of the variant with a confidence score that does not overlap with the first test, the variant can be called as possibly increased or decreased in the subject.

[0082] Several factors may affect the ability to detect a gene or variant at or near the detection or diagnostic limit. The gene or variant to be detected may be present in a low amount or concentration, which makes it impossible for the sequence analyzer to detect the gene or variant. For example, out of a million cell-free nucleic acid molecules to be analyzed, a gene mutation may be present in one cell-free nucleic acid molecule to be analyzed, and thus the variant base call is present at a frequency of 1 in a million. Because the gene mutation occurs at a low frequency relative to all other base calls at the same site, the sequencing analyzer may erroneously characterize the gene mutation as a non-variant base call. In such cases, the detection limit may generally refer to the ability of the gene analyzer or sequencer to detect a gene variation that is present at a very low frequency. Additionally, sequence errors or artifacts introduced from sequencing or amplification may make it difficult or impossible to distinguish between the errors and / or artifacts and the gene or gene variation to be detected. In such cases, the detection limit may refer to the ability to confidently distinguish between variant base calls and erroneous calls. The present disclosure provides a technique or techniques for detecting genetic variations at or below the limit of detection and / or within the threshold of detection.

[0083] As used herein, the term "diagnostic confidence index" generally refers to a representation, number, rank, score, degree, or value assigned to represent the presence of one or more genetic variants and how confident that presence is. A diagnostic confidence index can represent the probability of identifying one or more genetic variations in a subject's biological sample. For example, the representation can be a binary value or an alphanumeric rank from A to Z, among others. In yet another example, a diagnostic confidence index can have any value from 0 to 100, among others. In yet another example, a diagnostic confidence index can be represented by a range or degree, such as "low" or "high," "more" or "less," "increasing" or "decreasing." A low diagnostic confidence index represents the possibility that a detected genetic variant is noise (e.g., one cannot be very confident in the detected presence of a genetic variant). A high diagnostic confidence index means that for a detected genetic variant, the genetic variant is probably present. In some cases, if the diagnostic confidence index is less than 25-30 out of 100, the results may be unreliable.

[0084] The diagnostic confidence index of each variant can be adjusted to represent the confidence of predicting genetic variation. The confidence can be increased or decreased by using measurements from multiple samples at multiple time points or at the same or different time points. The diagnostic confidence can be further adjusted based on the detection of covariate variations. The diagnostic confidence index can be assigned by any of several statistical methods and can be based, at least in part, on the frequency with which measurements are observed over time.

[0085] As used herein, the term "covariate variation" or "covariate variant" generally refers to genetic variations that tend to vary together, e.g., the presence of one variation correlates with the presence of a covariate variation. Thus, if a variant is found below the diagnostic or detection limit, and a covariate variant is also detected above or below the detection limit, the sample is more likely to be positive for both variants, and they can be "called" as present in the sample. One example of a covariate variation is a driver mutation and a resistance mutation or a mutation of unknown significance. That is, after the drive mutation is present, other mutations such as resistance mutations may appear in the same gene, especially after cancer treatment and recurrence. As a non-limiting example, a driver mutation can be detected with high diagnostic confidence above the detection limit. However, due to insufficient sampling or noise, it may be difficult to confidently assess whether another genetic variation is present. If a genetic variation is generally present together with a driver mutation, and therefore the variant is a covariate variant (such as a passenger mutation or resistance mutation), the diagnostic confidence index of the genetic variant increases. The strength of the association between certain variants detected together can increase the probability, likelihood, and / or confidence that the genetic data detected below the limit of detection is a genetic variation.

[0086] As used herein, the term "DNA sequencing system" generally refers to a DNA sample preparation protocol used with a sequencing device. The DNA sample preparation protocol can cover library preparation, amplification, adapter ligation, single strand extension, among other molecular biology methods. The sequencing device can be any device capable of automating various sequencing methods or processes. Non-limiting examples of various sequencing methods or processes include Sanger sequencing, high throughput sequencing, pyrosequencing, sequencing by synthesis, single molecule sequencing, nanopore sequencing, semiconductor sequencing, sequencing by ligation, sequencing by hybridization, RNA-Seq (Illumina), digital gene expression (Helicos), next generation sequencing, single molecule sequencing by synthesis (SMSS) (Helicos), massively parallel sequencing, clonal single molecule arrays (Solexa), shotgun sequencing, Maxam-Gilbert sequencing, primer walking, and any other art-recognized sequencing method. A DNA sequencing system can include all the protocols for preparing a sample for sequencing on a particular sequencing instrument.

[0087] As used herein, the term "subject" generally refers to any organism used in the methods of the present disclosure. In some examples, the subject is a human, a mammal, a vertebrate, an invertebrate, a eukaryote, an archaea, a fungus, or a prokaryote. In some cases, the subject may be a human. The subject may be alive or dead. The subject may be a patient. For example, the subject may suffer from (or be suspected of suffering from) a disease and / or be under the care of a physician. The subject may be an individual undergoing treatment and / or diagnosis for a health or medical condition. The subject and / or family members may be related to another subject used in the methods of the present disclosure (e.g., sister, brother, mother, father, nephew, niece, aunt, uncle, grandparent, great-grandparent, cousin).

[0088] As used herein, the term "nucleic acid" generally refers to a molecule that includes one or more nucleic acid subunits. A nucleic acid can include one or more subunits selected from adenosine (A), cytosine (C), guanine (G), thymine (T) and uracil (U), or variants thereof. A nucleotide can include A, C, G, T, or U, or variants thereof. A nucleotide can include any subunit that can be incorporated into a growing nucleic acid chain. Such subunits can be A, C, G, T, or U, or any other subunit that is specific to one or more complementary A, C, G, T, or U, or is complementary to a purine (i.e., A or G, or variants thereof) or pyrimidine (i.e., C, T, or U, or variants thereof). A subunit can allow for the resolution of individual nucleic acid bases or groups of bases (e.g., AA, TA, AT, GC, CG, CT, TC, GT, TG, AC, CA, or their uracil counterparts). In some examples, the nucleic acid is deoxyribonucleic acid (DNA) or ribonucleic acid (RNA), or a derivative thereof. The nucleic acid may be single-stranded or double-stranded.

[0089] The term "genome" generally refers to the entirety of an organism's genetic information. A genome can be coded for by DNA or RNA. A genome can include coding regions that code for proteins as well as non-coding regions. A genome can include the sequences of all chromosomes of an organism together. For example, the human genome has a total of 46 chromosomes. All of these sequences together make up the human genome.

[0090] As used herein, the term "sample" generally refers to a biological sample. A sample may be or include blood, serum, plasma, vitreous, sputum, urine, tears, sweat, saliva, semen, mucosal excretion, mucus, spinal fluid, amniotic fluid, lymphatic fluid, etc. A sample may be a cell-free sample. A sample may include a nucleic acid molecule, such as a polynucleotide. The polynucleotide may be deoxyribonucleic acid (DNA) or ribonucleic acid (RNA). A cell-free polynucleotide may be fetal in origin (through fluid taken from a pregnant subject) or may be derived from the subject's own tissue. Detection limit / noise range

[0091] Polynucleotide sequencing can be likened to a problem in communication theory. The initial individual polynucleotide or ensemble of polynucleotides can be conceptualized as the original messenger. Tagging and / or amplification can be thought of as encoding the original messenger into a signal. Sequencing can be thought of as a communication channel. The output of the sequencer, e.g., sequence read data, can be thought of as the received signal. Bioinformatics processing can be thought of as a receiver that decodes the received signal to generate the sent messenger, e.g., nucleotide sequence(s). The received signal may contain artifacts, e.g., noise and distortion. Noise can be thought of as an unwanted random addition to the signal. Distortion can be thought of as a change in the amplitude of the signal or part of the signal.

[0092] Noise may be introduced through errors in the duplication and / or reading of a polynucleotide. For example, in a sequencing process, a single polynucleotide may first be subjected to amplification. Amplification may introduce errors, such that a subset of amplified polynucleotides may contain a base at a particular locus that is not the same as the original base at that locus. Furthermore, during the reading process, a base at any particular locus may be misread. As a result, a collection of sequence read data may contain a certain percentage of base calls at a locus that are not the same as the original base. In typical sequencing techniques, this error rate may be in the single digits, e.g., 2%-3%. In some cases, the error rate may be up to about 10%, up to about 9%, up to about 8%, up to about 7%, up to about 6%, up to about 5%, up to about 4%, up to about 3%, up to about 2%, or up to about 1%. When a collection of molecules that are all presumed to have the same sequence are sequenced, this noise is small enough that the original base can be identified with high confidence.

[0093] However, noise can be a significant problem if the set of parent polynucleotides, including the subset of polynucleotides that have it, differs at a particular locus. For example, this may be the case when cell-free DNA contains not only germline DNA but also DNA from another source, such as fetal DNA or DNA from cancer cells. In this case, true sequence variants may not be distinguishable from noise if the frequency of molecules with sequence variants may be in the same range as the frequency of errors introduced by the sequencing process. This may, for example, interfere with detecting sequence variants in a sample. For example, a sequence may have an error rate per base of 0.5-1%. Amplification bias and sequencing errors introduce noise into the final sequencing product. This noise can reduce the detection sensitivity. As a non-limiting example, a sequence variant whose frequency is less than the sequencing error rate may be mistaken for noise.

[0094] The noise range or detection limit refers to the case where the frequency of molecules with sequence variants is within the same range as the frequency of errors introduced by the sequencing process. "Detection limit" can also refer to the case where too few variant-containing molecules are sequenced for a variant to be detected. The frequency of molecules with sequence variants can be within the same range as the frequency of errors as a result of a small amount of nucleic acid molecules. As a non-limiting example, a sampled amount of nucleic acid, for example 100 ng, may contain a relatively small number of cell-free nucleic acid molecules, for example circulating tumor DNA molecules, so that the frequency of sequence variants may be low, even though variants may be present in the majority of circulating tumor DNA molecules. Alternatively, sequence variants are rare or found in only a very small amount of sampled nucleic acid, so that the variants detected cannot be distinguished from noise and / or sequencing errors. As a non-limiting example, at a particular locus, a genetic variant can only be detected in 0.1% to 5% of all read data for that locus.

[0095] Distortion can be revealed in the sequencing process as the difference in signal intensity, e.g., total number of sequence read data, generated by molecules of parent populations at the same frequency. Distortion can be introduced, for example, through amplification bias, GC bias, or sequencing bias. This may interfere with the detection of copy number variation in a sample. GC bias results in uneven representation of GC-rich or poor regions in sequence reads. Furthermore, amplification bias can distort the measurement of copy number variation by providing sequence read data with more or less amount than their actual value in the population.

[0096] Sequencing and / or amplification artifacts or errors, such as noise and / or distortion, can be reduced during polynucleotide sequencing.Sequencing and / or amplification artifacts or errors can be reduced using a variety of techniques for sequencing and sequence analysis.Various techniques can include sequencing methodologies and / or statistical methods.

[0097] One method of reducing noise and / or distortion is to filter sequence read data.As a non-limiting example, sequence read data can be filtered by requiring sequence read data to meet a quality threshold or by reducing GC bias.Such methods are generally performed on a set of sequence read data that is the output of a sequencer, and can be performed on each sequence read data, regardless of family structure (a subset of sequences that originate from a single original parent molecule).

[0098] Another way to reduce noise and / or distortion from a single individual molecule or from an ensemble of molecules is to group sequence read data into families derived from the original individual molecules to reduce noise and / or distortion from a single individual molecule or from an ensemble of molecules. Efficient conversion of individual polynucleotides in an initial sample of genetic material to sequence-ready tagged parent polynucleotides can increase the probability that individual polynucleotides in the initial sample of genetic material are represented in the sequence-ready sample. This can generate sequence information for more polynucleotides in the initial sample. Furthermore, high-yield generation of consensus sequences of tagged parent polynucleotides by high-rate sampling of progeny polynucleotides amplified from tagged parent polynucleotides, and collapsing the generated sequence read data into consensus sequences representing the sequences of the parent tagged polynucleotides can reduce noise introduced by amplification bias and / or sequencing errors and increase detection sensitivity. Collapsing sequence read data into consensus sequences is one way to reduce noise in messengers received from one molecule. Using a probability function to transform the received frequencies is another way to reduce noise and / or distortion. For an ensemble of molecules, grouping the read data into families and determining a quantitative measure of the families reduces, for example, distortion of the amount of molecules at each of a plurality of different loci. Again, collapsing the sequence read data of different families into a consensus sequence eliminates errors introduced by amplification and / or sequencing errors. Furthermore, determining the frequency of base calls based on probabilities derived from family information also reduces noise in the received messages from the ensemble of molecules.

[0099] By comparing the genetic variation in sequence read data with the genetic variation in other sequence read data, noise and / or distortion can be further reduced. Genetic variations observed in one sequence read data and again in other sequence read data increase the probability that the variant detected is actually a genetic variant and is not simply a sequencing error or noise. As a non-limiting example, if a genetic variation is observed in a first sequence read data and also observed in a second sequence read data, Bayesian inference can be applied as to whether the variation is actually a genetic variation and not a sequencing error.

[0100] The present disclosure provides a method for detecting variations in nucleic acid molecules, particularly those with frequencies within the noise range or below the detection limit.Variants that are first detected in nucleic acid molecules can be compared with other variants, such as variants at the same locus or covariate gene variants, to determine whether the variant can be detected more or less accurately.Variants can be detected in amplified nucleic acid molecules that are detected in sequence read data or collapsed sequence read data.

[0101] Repeated detection of variants can increase the probability, likelihood and / or confidence that variants are detected correctly. By comparing two or more sets of genetic data or genetic variations, variants can be repeatedly detected. Two or more sets of genetic variations can be both samples from multiple time points and different samples from the same time point (e.g., blood samples that are reanalyzed). In detecting variants within noise range or below noise threshold, resampling or repeated detection of low frequency variants increases the likelihood that the variant is actually a variant and not a sequencing error. Resampling can be from the same sample, for example, from the sample that is reanalyzed or rerun, or from the sample from a different time point.

[0102] As a non-limiting example, a genetic variant with a low confidence score can be detected at a frequency or amount below the detection limit or noise range.However, if the genetic variant is observed again, for example, in a previous sample at a later time point, or after reanalyzing the sample, the confidence score may increase.Thus, the variant can be detected with greater confidence, despite being present at a frequency or amount below the detection limit or noise range.In other cases, where the genetic variant is not observed again, for example, after resampling, the confidence score may remain constant or decrease.Alternatively, if the genetic variant observed at a particular locus contradicts the resampling result, the confidence score may decrease.

[0103] Covariate detection can increase the probability, likelihood and / or confidence that a variant is detected correctly. In covariate gene variants, the presence of one gene variant is associated with the presence of one or more other gene variants. Based on the detection of covariate gene variants, it may be possible to infer the presence of associated covariate gene variants even when associated gene variants are present below the detection limit. Alternatively, based on the detection of covariate gene variants, the diagnostic confidence index of associated gene variants can be increased. Furthermore, in some cases where covariate variants are detected, the detection threshold of covariate variants detected below the detection limit may be lowered. Non-limiting examples of covariate variants or genes include: driver mutations and resistance mutations, driver mutations and passenger mutations. Specific examples of covariants or genes are EGFR L858R activating mutations and EGFR T790M resistance mutations found in lung cancer. Numerous other covariate variants and genes are associated with various resistance mutations and will be recognized by those skilled in the art.

[0104] The present disclosure provides methods for detecting genetic variants where at least some of the variants are within a noise range or threshold. At the noise threshold or range, it may be difficult or impossible or difficult to detect the genetic variation with confidence. In some cases, the noise threshold provides a limit for detecting the genetic variation with statistical confidence. The noise threshold or range may overlap with the sequencing error rate. The noise threshold may be the same as the sequencing error rate. The noise threshold may be lower than the sequencing error rate. The noise threshold may be up to about 10%, up to about 9%, up to about 8%, up to about 7%, up to about 6%, up to about 5%, up to about 4%, up to about 3%, up to about 2%, or up to about 1%. In some cases, the noise range is about 0.5% to 10% per base. In some cases, the noise threshold is about 0.5% to 5% per base. In some cases, the noise threshold is about 0.5% to 1% per base. The terms noise and threshold may be used interchangeably.

[0105] Several types of genetic variants may be detected in nucleic acid molecules. Genetic variations may be interchangeably referred to as genetic variants or genetic abnormalities. Genetic variations may include single base substitutions, copy number variations, indels, and gene fusions. Combinations of these genetic variants may be detected. Non-limiting examples of additional genetic variants may include: transversions, transitions, inversions, deletions, aneuploidy, partial aneuploidy, polyploidy, chromosomal instability, chromosomal structural alterations, chromosomal fusions, gene truncations, gene amplifications, gene duplications, chromosomal damage, DNA damage, abnormal changes in chemical modifications of nucleic acids, abnormal changes in epigenetic patterns, and abnormal changes in nucleic acid methylation.

[0106] In one implementation, using measurements from multiple samples taken substantially simultaneously or across multiple time points, the diagnostic confidence index for each variant can be adjusted to represent the confidence in predicting the observed outcome of the copy number variation (CNV) or mutation. Measurements at multiple time points can be used to increase confidence in determining whether the cancer is progressing, in remission, or stable. The diagnostic confidence index can be assigned by any of several statistical methods and can be based, at least in part, on the frequency with which measurements are observed over time. For example, a statistical correlation of current and prior outcomes can be performed. Alternatively, a hidden Markov model can be constructed such that for each diagnosis, a maximum likelihood or maximum a posteriori decision can be made based on the frequency of occurrence of a particular test event from multiple measurements or time points. As part of this model, the probability of error of a particular decision and the resulting diagnostic confidence index can also be output. In this method, measurements of the parameters can be provided with confidence intervals, whether they are within the noise range or not. When tested over time, the predictive confidence of whether the cancer is progressing, stable, or in remission can be increased by comparing the confidence intervals over time. The two sampling times may be at least about 1 microsecond, 1 millisecond, 1 second, 10 seconds, 30 seconds, 1 minute, 10 minutes, 30 minutes, 1 hour, 12 hours, 1 day, 1 week, 2 weeks, 3 weeks, 1 month, or 1 year apart. The two times may be about 1 month to about 1 year, about 1 year to about 5 years, or about 3 months or less, 2 months, 1 month, 3 weeks, 2 weeks, 1 week, 1 day, or 12 hours apart.

[0107] FIG. 1 illustrates a first exemplary system that reduces error rates and biases that can be several orders of magnitude higher than those required for reliable detection of de novo genomic alterations associated with cancer. The process first captures genetic information by collecting a bodily fluid sample (blood, saliva, sweat, among others) as a source of genetic material, and then the process sequences the material (1). For example, polynucleotides in the sample can be sequenced to generate multiple sequence reads. The tumor burden in a sample containing polynucleotides can be estimated as the ratio of the relative number of sequence reads with variants to the total number of sequence reads generated from the sample. Also, in the case of copy number variants, the tumor burden can be estimated as the relative excess (in the case of gene duplication) or relative loss (in the case of gene exclusion) of the total number of sequence reads at the test and control loci. So, for example, one run can generate 1000 reads that map to cancer gene loci, of which 900 correspond to wild type and 100 correspond to cancer mutants, indicating a tumor burden of 10%. Further details regarding exemplary collection and sequencing of genetic material are described below in Figures 2-4.

[0108] The genetic information is then processed (2). Genetic variants are then identified. The variant may be a single nucleotide polymorphism (SNP) if it is a common genetic variant, a mutation if it is a rare genetic variant, or may be, for example, a copy number variation. This process then determines the frequency of the genetic variant in the sample containing the genetic material. Because this process is noisy, the process separates the information from the noise (3).

[0109] Sequencing methods have error rates. For example, Illumina's mySeq system can generate percent error rates in the low single digits. Therefore, for every 1000 sequence reads that map to a gene locus, about 50 reads (about 5%) can be expected to contain errors. Certain methodologies, such as those described in WO2014 / 149134 (Talasaz and Eltoukhy), the entire contents of which are incorporated by reference herein, can significantly reduce the error rate. Errors create noise that can give rise to ambiguous signals from cancers present at low levels in the sample. Thus, if a sample has a tumor burden at a level around the sequencing system error rate, for example, around 0.1%-5%, it can be difficult to distinguish signals corresponding to gene variants due to cancer from those due to noise.

[0110] Cancer diagnosis can be made by analyzing genetic variants even in the presence of noise. Analysis can be based on the frequency of sequence variants or levels of CNV (4) and can establish diagnostic confidence indications or levels for detecting genetic variants within the noise range (5).

[0111] The process then increases diagnostic confidence. This can be done using multiple measurements to increase the confidence of a diagnosis (6), or measurements at multiple time points can be used to determine whether the cancer is progressing, in remission, or stabilized (7).

[0112] Diagnostic reliability can be used to distinguish disease states.For example, cell-free polynucleotides collected from a subject can include polynucleotides derived from diseased cells, such as cancer cells, as well as polynucleotides derived from normal cells.Polynucleotides derived from cancer cells can have genetic variants, such as somatic mutations and copy number variants.When cell-free polynucleotides from a sample from a subject are sequenced, these cancer polynucleotides are detected as sequence variants or copy number variants. The relative amount of tumor polynucleotides in a sample of cell-free polynucleotides is referred to as the "tumor burden."

[0113] Whether or not the parameter measurements are within the noise range, they can be provided with confidence intervals. When examined over time, the confidence intervals can be compared over time to determine whether the cancer is progressing, stabilized, or in remission. If the confidence intervals do not overlap, this indicates the direction of the disease.

[0114] FIG. 1B shows a second exemplary system that reduces error rates and bias, which may be orders of magnitude higher than those required to reliably detect de novo genomic alterations associated with cancer. This is done by generating sequence read data from a specimen with a genetic analyzer, e.g., a DNA sequencer (10). The system then characterizes the subject's genetic information across two or more samples or time points (12). The system then uses information from the two or more sampling points or time points to generate test results that are adjusted in characterizing the subject's genetic information (14).

[0115] The test results can be adjusted by enhancing or counteracting the confidence index. For example, if the information from the first time point reinforces the information from the second time point, the process includes increasing the diagnostic confidence index in the subsequent or previous characterization. Alternatively, if the information from the first time point reinforces the information from the second time point, the process can increase the diagnostic confidence index in the subsequent characterization. If the information from the first time point contradicts the information from the second time point, the diagnostic confidence index in the subsequent characterization may be decreased. Alternatively, the process can leave the diagnostic confidence index in the subsequent characterization of the de novo information intact.

[0116] In one embodiment of Figure IB, the system compares the current sequence read data with the previous sequence read data by a genetic analyzer, e.g., a DNA sequencer, and updates the diagnostic confidence index accordingly. Based on the enhanced confidence signal, the system accurately generates a genetic profile of the subject's extracellular polynucleotide, where the genetic profile includes multiple data resulting from copy number variation and / or mutation analysis.

[0117] FIG. 1C shows a third exemplary system that reduces error rates and biases that may be orders of magnitude higher than those required to reliably detect de novo genomic alterations associated with cancer. As a non-limiting example, the system performs cancer detection by sequencing cell-free nucleic acid, where at least a portion of each gene of any group of at least 10, 25, 50, or 100 genes is sequenced (20); comparing current sequence read data with prior sequence read data and updating diagnostic confidence index accordingly (22). The system then detects the presence or absence of genetic alterations and / or the amount of genetic variation in the individual based on the diagnostic confidence index of the current sequence read data (24).

[0118] FIG. 1D shows yet another exemplary system that reduces error rates and biases that may be orders of magnitude higher than those required to reliably detect de novo genomic alterations associated with cancer. The system performs cancer detection, for example, by sequencing cell-free nucleic acids (30); comparing current sequence read data with prior sequence read data by a DNA sequencer and updating diagnostic confidence accordingly, where each consensus sequence corresponds to a unique polynucleotide in a set of tagged parent polynucleotides (32); and generating a genetic profile of extracellular polynucleotides in a subject, the genetic profile including a plurality of data resulting from analysis of copy number variations or rare mutations (34).

[0119] The system of Figures 1A-1D detects genetic variations in an initial sample of genetic material with high sensitivity. The method involves using one to three of the following tools: First, efficient conversion of individual polynucleotides in the initial sample of genetic material to sequence-ready tagged parent polynucleotides to increase the probability that the individual polynucleotides in the initial sample of genetic material will appear in the sequence-ready sample. This can generate sequence information for more polynucleotides in the initial sample. Second, high-yield generation of consensus sequences of tagged parent polynucleotides by high-rate sampling of progeny polynucleotides amplified from the tagged parent polynucleotides, and collapsing the generated sequence read data into consensus sequences representing the sequences of the parent tagged polynucleotides. This can reduce noise introduced by amplification bias and / or sequencing errors and can increase detection sensitivity. Third, noise in the detection of mutations and copy number variations is reduced by comparing a prior sample analysis to the current sample and increasing the diagnostic confidence index if the same mutations and copy number variations appeared in the prior analysis, or otherwise decreasing the diagnostic confidence index if this is the first time the sequences are observed.

[0120] This system detects genetic variations in the initial genetic material sample with high sensitivity. In one specific implementation, the operation of the system includes sample preparation, or extraction and isolation of cell-free polynucleotide sequences from bodily fluids; subsequent sequencing of cell-free polynucleotides by techniques utilized in the art; and application of bioinformatics tools to detect mutations and copy number variations compared to references. The detection of mutations and copy number variations is enhanced by comparing previous sample analysis with the current sample, and increasing diagnostic confidence index if the same mutations and copy number variations appear in the previous analysis, otherwise decreasing or leaving unchanged if this is the first time the sequence is observed. The system and method can also contain a database or collection of different mutations or copy number variation profiles of different diseases, which are used as additional references in helping to detect disease mutations, copy number variation profiling or general genetic profiling.

[0121] After collecting the sequencing data of cell-free polynucleotide sequence, one or more bioinformatics processes can be applied to the sequence data to detect genetic features or variations, such as changes in epigenetic markers, including but not limited to copy number variation, mutation, or methylation profile.In some cases where copy number variation analysis is desired, sequence data can be: 1) aligned with reference genome; 2) filtered and mapped; 3) divided into sequence windows or bins; 4) coverage read data is counted for each window; 5) coverage read data can then be normalized using probabilistic or statistical modeling algorithms; and 6) output files can be generated that reflect the individual copy number status at various positions of genome.In other cases where mutation analysis is desired, sequence data can be: 1) aligned with reference genome; 2) filtered and mapped; 3) variant base frequency is calculated based on the coverage read data of that particular base; 4) variant base frequency is normalized using probabilistic, statistical, or probabilistic modeling algorithms; and 5) output files can be generated that reflect the mutation status at various positions of genome. Temporal information from current and prior analyses of the patient or subject is used to enhance the analysis and decisions.

[0122] There can be a variety of different reactions and / or operations within the systems and methods disclosed herein, examples of which include, but are not limited to, nucleic acid sequencing, nucleic acid quantification, sequencing optimization, gene expression detection, gene expression quantification, genomic profiling, cancer profiling, or analysis of expressed markers. Furthermore, the systems and methods have numerous medical applications. For example, it can be used for identifying, detecting, diagnosing, treating, monitoring, staging or predicting the risk of various genetic and non-genetic diseases and disorders, including cancer. It can be used to evaluate the subject's response to different treatments of genetic and non-genetic diseases, or to provide information on disease progression and prognosis. Polynucleotide isolation and extraction

[0123] The systems and methods of this disclosure can have a wide variety of applications in the manipulation, preparation, identification and / or quantification of nucleic acids, including cell-free polynucleotides. Examples of nucleic acids or polynucleotides include, but are not limited to, DNA, RNA, amplicons, cDNA, dsDNA, ssDNA, plasmid DNA, cosmid DNA, high molecular weight (MW) DNA, chromosomal DNA, genomic DNA, viral DNA, bacterial DNA, mtDNA (mitochondrial DNA), mRNA, rRNA, tRNA, nRNA, siRNA, snRNA, snoRNA, scaRNA, microRNA, dsRNA, ribozymes, riboswitches and viral RNA (e.g., retroviral RNA).

[0124] Cell-free polynucleotides can be derived from a variety of sources, including human, mammalian, non-human mammalian, ape, monkey, chimpanzee, reptile, amphibian, or avian sources. Additionally, samples can be extracted from a variety of animal bodily fluids that contain cell-free sequences, including, but not limited to, blood, serum, plasma, vitreous, sputum, urine, tears, sweat, saliva, semen, mucosal excretions, mucus, spinal fluid, amniotic fluid, lymphatic fluid, and the like. Cell-free polynucleotides can be fetal in origin (through fluids taken from a pregnant subject) or can be derived from the subject's own tissues.

[0125] Isolation and extraction of cell-free polynucleotides can be performed through collection of bodily fluids using a variety of techniques. In some cases, collection can include aspirating bodily fluids from a subject using a syringe. In other cases, collection can include pipetting or direct collection of the fluid into a collection container.

[0126] After collecting body fluid, cell-free polynucleotides can be isolated and extracted using various techniques available in the art.In some cases, cell-free DNA can be isolated, extracted and prepared using commercial kits such as Qiagen Qiamp® Circulating Nucleic Acid Kit Protocol.In other examples, Qiagen Qubit™ dsDNA HS Assay Kit Protocol, Agilent™ DNA1000 Kit or TruSeq™ Sequencing Library Preparation; Low Throughput (LT) Protocol can be used.

[0127] Generally, cell-free polynucleotides are extracted and isolated from body fluids through a partitioning step in which cell-free DNA, as found in solution, is separated from cells and other non-soluble components of the body fluid. Partitioning can include techniques such as, but not limited to, centrifugation or filtration. In other cases, cells are not partitioned from cell-free DNA first, but rather dissolved. In this example, intact cellular genomic DNA is partitioned through selective precipitation. Cell-free polynucleotides, including DNA, can remain soluble and can be separated and extracted from insoluble genomic DNA. Generally, after addition of buffer and other washing steps specific to different kits, isopropanol precipitation can be used to precipitate DNA. Further clean-up steps, such as silica-based columns, can be used to remove contaminants or salts. General steps can be optimized for specific applications. Non-specific bulk carrier polynucleotides, for example, can be added throughout the reaction to optimize certain aspects of the procedure, such as yield.

[0128] Isolation and purification of cell-free DNA can be accomplished using any methodology, including but not limited to the use of commercially available kits and protocols provided by companies such as Sigma Aldrich, Life Technologies, Promega, Affymetrix, IBI, etc. The kits and protocols do not have to be commercially available.

[0129] After isolation, in some cases, the cell-free polynucleotides are premixed with one or more additional materials, such as one or more reagents (eg, ligases, proteases, polymerases) prior to sequencing.

[0130] One way to increase the conversion efficiency involves the use of ligases engineered for optimal reactivity with single-stranded DNA, such as ThermoPhage ssDNA ligase derivatives. Such ligases bypass the traditional steps in library preparation of end repair and A-tailing, which can have poor efficiency and / or accumulated losses due to intermediate clean-up steps, and allow doubling the probability that either sense or antisense starting polynucleotides are converted into properly tagged polynucleotides. It also converts double-stranded polynucleotides that may carry overhangs that cannot be sufficiently blunted by common end repair reactions. The optimal reaction conditions for this ssDNA reaction are as follows: 1× reaction buffer (50 mM MOPS (pH 7.5), 1 mM DTT, 5 mM MgCl2, 10 mM KCl). Incubated at 65° C. for 1 hour with 50 mM ATP, 25 mg / ml BSA, 2.5 mM MnCl2, 200 pmol 85 nt ssDNA oligomers and 5 U ssDNA ligase. Subsequent amplification using PCR can further convert the tagged single-stranded library to a double-stranded library, giving an overall conversion efficiency well above 20%. Other methods to increase the conversion rate, for example to above 10%, include, for example, any of the following, alone or in combination: annealing-optimized molecular inversion probes, blunt-end ligation with a well-controlled polynucleotide size range, sticky-end ligation or an upfront multiplex amplification step with or without the use of fusion primers. Molecular barcoding of cell-free polynucleotides

[0131] The disclosed system and method can also allow tagging and tracking of cell-free polynucleotides to allow subsequent identification and origin of specific polynucleotides.This feature is in contrast to other methods that use pooled or multiplexed reactions and only provide measurement or analysis as the average of multiple samples.Here, the assignment of identifiers to individual polynucleotides or subgroups of polynucleotides allows unique identity to be assigned to individual sequences or fragments of sequences.This can allow data to be obtained from individual samples and is not limited to the average of samples.

[0132] In some cases, nucleic acids or other molecules derived from a single strand can share a common tag or identifier, and can therefore be later identified as being derived from this strand. Similarly, all fragments derived from a single strand of nucleic acid can be tagged with the same identifier or tag, which allows for subsequent identification of the fragments from the parent strand. In other cases, gene expression products (e.g., mRNA) can be tagged to quantify expression, thereby counting barcodes or barcodes combined with sequences to which they are attached. In still other cases, the system and method can be used as a PCR amplification control. In such cases, multiple amplification products from a PCR reaction can be tagged with the same tag or identifier. If the products are later sequenced to demonstrate sequence differences, the differences between products with the same identifier can be due to PCR errors.

[0133] Moreover, individual sequences can be identified based on the characteristics of the sequence data of the read itself. For example, detection of unique sequence data at the beginning (start) and end (stop) of each sequencing read can be used alone or in combination with the length or number of base pairs of the unique sequence of each sequence read to assign a unique identity to each molecule. Thus, fragments from a single strand of nucleic acid assigned a unique identity can allow subsequent identification of fragments from the parent strand. This can be used in conjunction with the initial starting genetic material to bottleneck and limit diversity.

[0134] Furthermore, the length of the sequencing read can be used alone or in combination with the use of barcodes, using unique sequence data at the beginning (start) and end (end) of each sequencing read. In some cases, as described herein, the barcode can be unique. In other cases, the barcode itself may not be unique. In this case, the use of non-unique barcodes combined with sequence data at the beginning (start) and end (end) of each sequencing read and the length of the sequencing read can allow for the assignment of unique identities to individual sequences. Similarly, this allows fragments from a single strand of nucleic acid to be assigned unique identities, allowing subsequent identification of fragments from the parent strand.

[0135] In general, the methods and systems provided herein are useful for preparing cell-free polynucleotide sequences for downstream application sequencing reactions. The sequencing method can be classical Sanger sequencing. Sequencing methods can include, but are not limited to, high-throughput sequencing, pyrosequencing, sequencing by synthesis, single molecule sequencing, nanopore sequencing, semiconductor sequencing, sequencing by ligation, sequencing by hybridization, RNA-Seq (Illumina), digital gene expression (Helicos), next-generation sequencing, single molecule sequencing by synthesis (SMSS) (Helicos), massively parallel sequencing, clonal single molecule arrays (Solexa), shotgun sequencing, Maxam-Gilbert sequencing, primer walking, and any other sequencing method recognized in the art. Assigning barcodes to cell-free polynucleotide sequences

[0136] The systems and methods disclosed herein can be used in applications involving the assignment of unique or non-unique identifiers or molecular barcodes to cell-free polynucleotides. The identifiers can be barcode oligonucleotides used to tag the polynucleotides; however, in some cases, different unique identifiers are used. For example, in some cases, the unique identifiers are hybridization probes. In other cases, the unique identifiers are dyes, in which case the attachment can include inserting the dye into the analyte molecule (such as inserting into DNA or RNA) or binding to a dye-labeled probe. In still other cases, the unique identifiers can be nucleic acid oligonucleotides, in which case the attachment to the polynucleotide sequence can include incorporation through a ligation reaction between the oligonucleotide and the sequence or PCR. In other cases, the reaction can include the addition of a metal isotope to the analyte directly or via an isotope-labeled probe. In general, the assignment of unique or ratio-specific identifiers or molecular barcodes in the reactions of this disclosure can follow the methods and systems described, for example, by U.S. Patent Publication Nos. 2001 / 0053519, 2003 / 0152490, 2011 / 0160078, and U.S. Patent No. 6,582,908, each of which is incorporated by reference herein in its entirety.

[0137] The method can include attaching an oligonucleotide barcode to a nucleic acid analyte through an enzymatic reaction, including but not limited to a ligation reaction. For example, a ligase enzyme can covalently attach a DNA barcode to fragmented DNA (e.g., high molecular weight DNA). After attachment of the barcode, the molecule can be subjected to a sequencing reaction.

[0138] However, other reactions can also be used. For example, an oligonucleotide primer containing a barcode sequence can be used in an amplification reaction (e.g., PCR, qPCR, reverse transcriptase PCR, digital PCR, etc.) of a DNA template analyte, thereby generating a tagged analyte. After assignment of a barcode to each cell-free polynucleotide sequence, the pool of molecules can be sequenced.

[0139] In some cases, PCR can be used for global amplification of cell-free polynucleotide sequences. This can include using adapter sequences that can be first ligated to different molecules and then PCR amplified using universal primers. PCR for sequencing can be performed using any methodology, including but not limited to using commercial kits provided by Nugen (WGA kit), Life Technologies, Affymetrix, Promega, Qiagen, etc. In other cases, only certain target molecules in a population of cell-free polynucleotide molecules can be amplified. Specific primers can be used with adapter ligation to selectively amplify certain targets for downstream sequencing.

[0140] Unique identifiers (e.g., oligonucleotide barcodes, antibodies, probes, etc.) can be randomly or non-randomly introduced into the cell-free polynucleotide sequences. In some cases, they are introduced into the microwells in an expected ratio of unique identifiers. For example, the unique identifiers can be loaded such that more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 50, 100, 500, 1000, 5000, 10000, 50,000, 100,000, 500,000, 1,000,000, 10,000,000, 50,000,000 or 1,000,000,000 unique identifiers are loaded per genomic sample. In some examples, the unique identifiers may be loaded such that less than about 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 50, 100, 500, 1000, 5000, 10000, 50,000, 100,000, 500,000, 1,000,000, 10,000,000, 50,000,000 or 1,000,000,000 unique identifiers are loaded per genomic sample. In some examples, the average number of unique identifiers loaded per sample genome is less than or equal to about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 50, 100, 500, 1000, 5000, 10000, 50,000, 100,000, 500,000, 1,000,000, 10,000,000, 50,000,000 or 1,000,000,000 unique identifiers per genome sample.

[0141] In some cases, the unique identifiers can be of various lengths such that each barcode is at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 50, 100, 500, 1000 base pairs. In other examples, the barcodes can include less than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 50, 100, 500, 1000 base pairs.

[0142] In some cases, the unique identifier may be an oligonucleotide of predetermined or random or semi-random sequence. In other cases, multiple barcodes may be used, and thus the barcodes are not necessarily unique to each other among the plurality. In this example, the barcodes may be ligated to individual molecules such that the combination of barcodes and sequences may be ligated to generate unique sequences that can be tracked individually. As described herein, detection of non-unique barcodes in combination with sequence data at the beginning (start) and end (end) portions of the sequence read data may allow assignment of a unique identity to a particular molecule. The length or number of base pairs of the individual sequence read data may also be used to assign a unique identity to such a molecule. As described herein, fragments from a single strand of nucleic acid that are assigned a unique identity may thereby allow subsequent identification of fragments from the parent strand. In this manner, polynucleotides in a sample may be tagged as unique or substantially unique.

[0143] The unique identifiers can be used to tag a wide range of analytes, including but not limited to RNA or DNA molecules. For example, the unique identifiers (e.g., barcode oligonucleotides) can be attached to a complete strand of nucleic acid or to a fragment of a nucleic acid (e.g., fragmented genomic DNA, fragmented RNA). The unique identifiers (e.g., oligonucleotides) can also be attached to gene expression products, genomic DNA, mitochondrial DNA, RNA, mRNA, etc.

[0144] In many applications, it will be important to determine whether individual cell-free polynucleotide sequences each receive a different unique identifier (e.g., oligonucleotide barcode). If the population of unique identifiers introduced into the system and method is not significantly diverse, different analytes can possibly be tagged with the same identifier. The systems and methods disclosed herein can allow detection of cell-free polynucleotide sequences tagged with the same identifier. In some cases, a reference sequence may be included with the population of cell-free polynucleotide sequences to be analyzed. The reference sequence may be, for example, a nucleic acid with a known sequence and a known amount. If the unique identifier is an oligonucleotide barcode and the analyte is a nucleic acid, the tagged analyte can then be sequenced and quantified. These methods can indicate whether one or more fragments and / or analytes are assigned the same barcode.

[0145] The methods disclosed herein may include utilizing the necessary reagents for the assignment of barcodes to analytes. For ligation reactions, reagents including but not limited to ligase enzymes, buffers, adapter oligonucleotides, multiple unique identifier DNA barcodes, etc. may be loaded into the system and method. For enrichment, reagents including but not limited to multiple PCR primers, oligonucleotides containing unique identification sequences or barcode sequences, DNA polymerase, DNTPs, buffers, etc. may be used in preparation for sequencing.

[0146] In general, the methods and systems of this disclosure may utilize the methods of U.S. Pat. No. 7,537,897, which is fully incorporated by reference herein, in using molecular barcodes to count molecules or analytes.

[0147] In a sample containing fragmented genomic DNA from multiple genomes, e.g., cell-free DNA (cfDNA), there is some probability that more than one polynucleotide from different genomes will have the same start and end positions ("duplicates" or "cognates"). The expected number of duplicates starting at any position is a function of the number of haploid genome equivalents in the sample and the distribution of fragment sizes. For example, cfDNA has a peak of fragments of about 160 nucleotides, with most fragments in this peak falling within the range of about 140 to 180 nucleotides. Thus, cfDNA from a genome of about 3,000,000,000 bases (e.g., the human genome) will have approximately 20,000,000 fragments (2×10 7 ) polynucleotide fragments. A DNA sample of about 30 ng can contain about 10,000 haploid human genome equivalents. (Similarly, a DNA sample of about 100 ng can contain about 30,000 haploid human genome equivalents.) About 10,000 (10 4 A sample containing approximately 200,000,000,000 (2 × 10) haploid genome equivalents would contain approximately 200,000,000,000 (2 × 10) 11 ) individual polynucleotide molecules. It has been determined experimentally that in a sample of about 10,000 haploid genome equivalents of human DNA, there are about 3 replicate polynucleotides beginning at any given position. Thus, such a collection can have about 6×10 10 ~8×10 10 (About 60,000,000,000 to 80,000,000,000, e.g., about 70,000,000,000 (7×10 10 )) a diversity of differently sequenced polynucleotide molecules.

[0148] The probability of correctly identifying a molecule depends on the initial number of genome equivalents, the length distribution of the sequenced molecules, the sequence uniformity, and the number of tags. When the tag number is equal to 1, it is that it does not have a unique tag or is untagged. The table below lists the probability of correctly identifying a molecule as unique assuming the general cell-free size distribution above. [Table 1]

[0149] In this case, after sequencing the genomic DNA, it may not be possible to determine which sequence reads come from which parent molecule. This problem can be reduced by tagging the parent molecules with a sufficient number of unique identifiers (e.g., tag numbers) so that two replicate molecules, i.e., molecules with the same start and end positions, are likely to have different unique identifiers, so that sequence reads can be traced back to a specific parent molecule. One approach to this problem is to uniquely tag all or almost all the different parent molecules in the sample. However, depending on the number of haploid gene equivalents and the distribution of fragment sizes in the sample, this may require billions of different unique identifiers.

[0150] The above methods can be cumbersome and expensive. Individual polynucleotide fragments in a genomic nucleic acid sample (e.g., a genomic DNA sample) can be identified as unique by tagging with a non-unique identifier, e.g., tagging each individual polynucleotide fragment as non-unique. As used herein, a collection of molecules can be considered "uniquely tagged" if at least 95% of the molecules in the collection each have an identification tag ("identifier") that is not shared by any other molecule in the collection ("unique tag" or "unique identifier"). For unique tags, the number of tags can be less than the number of unique molecules in the sample. For unique tags, the number of tags can be less than 10% of the number of molecules in the sample. For unique tags, the number of tags can be less than 1% of the number of molecules in the sample. A collection of molecules can be considered "tagged as non-unique" if at least 1%, at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, or at least or about 50% of the molecules in the collection each have an identification tag shared by at least one other molecule in the collection ("non-unique tag" or "non-unique identifier"). In some embodiments, for a population tagged as non-unique, 1% or less, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% of the molecules are tagged as unique. In some embodiments, for unique tagging, at least twice as many different tags are used as the estimated number of molecules in the sample. The number of different identification tags used to tag the molecules in a collection can be within a range between, for example, any of 2, 4, 8, 16 or 32 at the lower end of the range and any of 50, 100, 500, 1000, 5000 and 10,000 at the higher end of the range. Thus, for example, a collection of 100,000,000,000 to 1,000,000,000,000 molecules can be tagged with between 4 and 100 different identification tags.

[0151] The present disclosure provides methods and compositions in which a population of polynucleotides in a sample of fragmented genomic DNA is tagged with n different unique identifiers. In some embodiments, n is at least 2 and 100,000. * n is less than or equal to z, where z is a measure of central tendency (e.g., mean, median, mode) of the expected number of replicate molecules with the same start and end positions. In some embodiments, z is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or greater than 10. In some embodiments, z is less than 10, less than 9, less than 8, less than 7, less than 6, less than 5, less than 4, less than 3. In certain embodiments, n is at least any of 2*z, 3*z, 4*z, 5*z, 6*z, 7*z, 8*z, ​​9*z, 10*z, 11*z, 12*z, 13*z, 14*z, 15*z, 16*z, 17*z, 18*z, 19*z, or 20*z (e.g., a lower limit). In another embodiment, n is less than or equal to 100,000*z, 10,000*z, 1000*z, or 100*z (e.g., upper limits). Thus, n can be in a range between any combination of these lower and upper limits. In certain embodiments, n is less than or equal to 5 * z to 15 * Between z, 8 * z to 12 * z, or about 10 *z. For example, a haploid human genome equivalent has about 3 picograms of DNA. About 1 microgram of DNA sample contains about 300,000 haploid human genome equivalents. In some embodiments, the number n can be 5 to 95, 6 to 80, 8 to 75, 10 to 70, 15 to 45, 24 to 36, or about 30. In some embodiments, the number n is less than 96. For example, the number n is 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 109, 108, 109, 101, 109, 102, 103, 104, 105, 106, 107, 108, 109, 109, In some cases, the number n may be greater than or equal to 2, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, or 95. In some cases, the number n may be greater than 0 but less than 100, 99, 98, 97, 96, 95, 94, 93, 92, 91, or 90. In some cases, the number n is 64. The number n may be less than 75, less than 50, less than 40, less than 30, less than 20, less than 10, or less than 5. As long as at least some of the duplicates or cognate polynucleotides have unique identifiers, i.e., different tags, improved sequencing can be achieved. However, in certain embodiments, the number of tags used is selected so that there is at least a 95% probability that all duplicate molecules containing the same start and end sequences have unique identifiers.

[0152] Some embodiments provide a method for performing a ligation reaction in which a parent polynucleotide in a sample is mixed with a reaction mixture containing y different barcode oligonucleotides, where y is the square root of n. The ligation can result in random attachment of the barcode oligonucleotides to the parent polynucleotides in the sample. The reaction mixture can then be incubated under ligation conditions sufficient to perform ligation of the barcode oligonucleotides to the parent polynucleotides in the sample. In some embodiments, random barcodes selected from y different barcode oligonucleotides are ligated to both ends of the parent polynucleotide. The random ligation of y barcodes to one or both ends of the parent polynucleotide can be performed by ligating y barcodes to one or both ends of the parent polynucleotide. 2 This can result in the generation of about 36 unique identifiers. For example, a sample containing about 10,000 haploid human genome equivalents of cfDNA can be tagged with about 36 unique identifiers. The unique identifiers can include six unique DNA barcodes. Ligation of six unique barcodes to both ends of a polynucleotide can result in the generation of 36 possible unique identifiers.

[0153] In some embodiments, a sample containing about 10,000 haploid human genome equivalents of DNA is tagged with 64 unique identifiers, where the 64 unique identifiers are generated by ligating 8 unique barcodes to both ends of a parent polynucleotide. The ligation efficiency of the reaction can be greater than 10%, greater than 20%, greater than 30%, greater than 40%, greater than 50%, greater than 60%, greater than 70%, greater than 80%, or greater than 90%. The ligation conditions can include the use of bidirectional adapters that can bind to either end of a fragment and still be amplified. In contrast to tailing with forked adapters, the ligation conditions can include blunt-end ligation. The ligation conditions can include careful titration of the amount of adapter and / or barcode oligonucleotide. The ligation conditions can include the use of adapters and / or barcode oligonucleotides in a molar excess of more than 2x, more than 5x, more than 10x, more than 20x, more than 40x, more than 60x, more than 80x, (e.g., about 100x) compared to the amount of parent polynucleotide fragments in the reaction mixture. The ligation conditions can include the use of T4 DNA ligase (e.g., NEBNExt Ultra Ligation Module). In an example, 18 microliters of ligase master mix is ​​used with 90 microliters of ligation (18 parts of 90) and ligation enhancer. Thus, tagging a parent polynucleotide with n unique identifiers can include the use of a number y of different barcodes, where y is the square root of n. Samples tagged in such a manner can be those having fragmented polynucleotides, such as genomic DNA, such as cfDNA, ranging from about 10 ng to about 100 ng, about 1 μg, or about 10 μg. The number y of barcodes used to identify parent polynucleotides in a sample can depend on the amount of nucleic acid in the sample.

[0154] The present disclosure also provides compositions of tagged polynucleotides. The polynucleotides can include fragmented DNA, e.g., cfDNA. The set of polynucleotides in the composition that are mapped to the mappable base positions of the genome can be tagged as non-unique, i.e., the number of different identifiers is at least 2 and may be less than the number of polynucleotides that are mapped to the mappable base positions. A composition of between about 10 ng and about 10 μg (e.g., between about 10 ng and 1 μg, between about 10 ng and 100 ng, between about 100 ng and 100 μg, between about 100 ng and 1 μg, between about 1 μg and 10 μg) can have between 2, 5, 10, 50, or 100, and between 100, 1000, 10,000, or 100,000 different identifiers. For example, between 5 and 100 different identifiers can be used to tag the polynucleotides in such a composition.

[0155] FIG. 2 shows an exemplary process for analyzing polynucleotides in a sample of initial genetic material. First, a sample containing the initial genetic material is provided and cell-free DNA can be extracted (50). The sample can contain a low abundance of the target nucleic acid. For example, nucleic acid from a normal or wild-type genome (e.g., a germline genome) can predominate in a sample that also contains 20% or less, 10% or less, 5% or less, 1% or less, 0.5% or less, or 0.1% or less of nucleic acid from at least one other genome containing a genetic variation, such as a cancer genome or a fetal genome, or a genome from another individual or species. The sample can include, for example, cell-free nucleic acid, or cells containing nucleic acid with appropriate oversampling of the original polynucleotides by sequencing or genetic analysis processes.

[0156] The initial genetic material is then converted to a set of tagged parent polynucleotides and sequenced to generate sequence reads (52). This step generates a plurality of genome fragment sequence reads. In some cases, these sequence reads can contain barcode information. In other instances, barcodes are not utilized. Tagging can include attaching sequenced tags to molecules in the initial genetic material. The sequenced tags can be selected such that every unique polynucleotide that maps to the same reference sequence has a unique identifying tag. The conversion can be performed with high efficiency, for example at least 50%. The set of tagged parent polynucleotides can be amplified to generate a set of amplified progeny polynucleotides. The amplification can be, for example, 1,000-fold. The set of amplified progeny polynucleotides is sampled for sequencing at a sampling rate such that the sequence reads generated (1) cover a target number of unique molecules in the set of tagged parent polynucleotides, and (2) cover the unique molecules in the set of tagged parent polynucleotides at a target coverage factor (e.g., 5-10 times coverage of the parent polynucleotides). The set of sequence reads is collapsed to generate a set of consensus sequences corresponding to the unique tagged parent polynucleotides. The sequence reads can be qualified for inclusion in the analysis. For example, sequence reads that fail to meet a quality control score can be removed from the pool. The sequence reads can be sorted into families representing the reads of progeny molecules derived from a particular unique parent molecule. For example, a family of amplified progeny polynucleotides can comprise amplified molecules derived from a single parent polynucleotide. By comparing the sequences of the progeny in the family, a consensus sequence of the original parent polynucleotide can be inferred. This generates a set of consensus sequences representing the unique parent polynucleotides in the tagged pool.

[0157] The process then assigns a confidence score for the sequence (54). After sequencing, the reads are assigned a quality score. The quality score may be an indication of the reads that indicate whether these reads may be useful in subsequent analysis based on a threshold. In some cases, some reads are not of sufficient quality or length to perform the subsequent mapping step. Sequencing reads with a certain quality score (e.g., above 90%) can be filtered out of the data. Genomic fragment reads that meet a specified quality score threshold are mapped to a reference genome or to a template sequence that is known to contain no copy number variations. After mapping alignment, the sequence reads are assigned a mapping score. The mapping score may be a representation or reads that are mapped back to a reference sequence that indicates whether each position is uniquely mappable or not. In some cases, the reads may be sequences that are not relevant to the copy number variation analysis. For example, some sequence reads may originate from contaminant polynucleotides. Sequencing reads having a mapping score of at least 90%, 95%, 99%, 99.9%, 99.99% or 99.999% can be filtered out from the dataset. In other cases, sequencing reads assigned a mapping score below a predetermined percentage can be filtered out from the dataset.

[0158] Genomic fragment reads that meet a specified quality score threshold are mapped to a reference genome or a template sequence that is known not to contain copy number variation. After mapping alignment, sequence reads are assigned a mapping score. In some cases, the reads may be sequences that are not relevant to copy number variation analysis. After data filtering and mapping, the multiple sequence read data generate chromosomal regions of coverage. These chromosomal regions can be divided into windows or bins of various lengths. The windows or bins can be at least 5kb, 10, kb, 25kb, 30kb, 35, kb, 40kb, 50kb, 60kb, 75kb, 100kb, 150kb, 200kb, 500kb, or 1000kb. A window or bin can also have up to 5kb, 10, kb, 25kb, 30kb, 35, kb, 40kb, 50kb, 60kb, 75kb, 100kb, 150kb, 200kb, 500kb, or 1000kb of bases. A window or bin can also be about 5kb, 10, kb, 25kb, 30kb, 35, kb, 40kb, 50kb, 60kb, 75kb, 100kb, 150kb, 200kb, 500kb, or 1000kb.

[0159] For coverage normalization, each window or bin is selected to contain approximately the same number of mappable bases. In some cases, each window or bin in a chromosomal region can contain the exact number of mappable bases. In other cases, each window or bin can contain a different number of mappable bases. Furthermore, each window or bin may not overlap with adjacent windows or bins. In other cases, a window or bin may overlap with another adjacent window or bin. In some cases, a window or bin may overlap by at least 1 bp, 2 bp, 3 bp, 4 bp, 5 bp, 10 bp, 20 bp, 25 bp, 50 bp, 100 bp, 200 bp, 250 bp, 500 bp, or 1000 bp.

[0160] In some cases, each of the window regions can be sized so that they contain approximately the same number of uniquely mappable bases. The mappability of each base that makes up the window region is determined and used to generate a mappability file that contains a representation of the back-mapped reference-to-reference reads for each file. The mappability file contains one column per position indicating whether each position is uniquely mappable or not.

[0161] Furthermore, certain windows that are known to be difficult to sequence across the genome or contain significant GC bias can be filtered out of the data set. For example, regions known to be near the centromeres of chromosomes (i.e., centromeric DNA) are known to contain highly repetitive sequences that can generate false positive results. These regions can be filtered out. Other regions of the genome, such as regions that contain unusually high concentrations of other highly repetitive sequences, such as microsatellite DNA, can be filtered out of the data set.

[0162] The number of windows analyzed can also vary. In some examples, at least 10, 20, 30, 40, 50, 100, 200, 500, 1000, 2000, 5,000, 10,000, 20,000, 50,000, or 100,000 windows are analyzed. In other examples, the number of windows analyzed is up to 10, 20, 30, 40, 50, 100, 200, 500, 1000, 2000, 5,000, 10,000, 20,000, 50,000, or 100,000 windows are analyzed.

[0163] In the case of an exemplary genome derived from a cell-free polynucleotide sequence, the next step involves determining the read coverage of each window region. This can be performed using reads with or without barcodes. In the absence of barcodes, the previous mapping step provides coverage of the different base positions. Sequence reads that have sufficient mapping and quality scores and fall into the unfiltered chromosome window can be counted. The number of coverage reads can be assigned a score for each mappable location. In the case of including barcodes, all sequences with the same barcode, physical property, or combination of the two can be collapsed into one read since they all originate from the sample parent molecule. This step reduces bias that may have been introduced during any of the previous steps, such as the step involving amplification. For example, if one molecule is amplified 10-fold while the other is amplified 1000-fold, each molecule will only be represented once after the collapse, thereby negating the effects of uneven amplification. Only reads with unique barcodes can be counted for each mappable location and can affect the score assigned. For this reason, it is important to perform the barcode ligation step in a manner that is optimized to generate the least amount of bias. The sequence of each base is aligned as the most predominant nucleotide read data at that specific position. Furthermore, the number of unique molecules at each position can be counted to guide simultaneous quantification at each position. This step reduces bias that may have been introduced during any of the previous steps, such as steps involving amplification.

[0164] To identify copy number variation in chromosomal region, the individual copy number status of each window region can be utilized.In some cases, all adjacent window regions with the same copy number can be merged into a segment to report the presence or absence of copy number variation status.In some cases, various windows can be filtered before they are merged with other segments.

[0165] When determining the nucleic acid read data coverage for each window, the coverage of each window can be normalized by the average coverage of its sample.It may be desirable to use such an approach to sequence both test subjects and controls under similar conditions.The read data coverage of each window can then be expressed as a ratio across similar windows.

[0166] The nucleic acid read data coverage ratio for each window under test can be determined by dividing the read data coverage for each window region in the test sample by the read data coverage for the corresponding window region in the control sample.

[0167] The process then examines the prior confidence scores of each read family for the patient (58). This information is stored in a database. Prior analysis of the patient's test results can be used to refine the confidence scores, as detailed in Figure 2. This information is used to infer the frequency of each sequence read at a locus in the set of tagged parent polynucleotides based on the confidence scores between the sequence read families (60). The historical database is then updated with the current confidence scores for future use (62). In this manner, consensus sequences can be generated from families of sequence reads to improve noise removal.

[0168] Turning now to Figure 3, the process receives genetic material from a blood sample or other body sample (102). The process converts polynucleotides from the genetic material into tagged parent nucleotides (104). The tagged parent nucleotides are amplified to produce amplified progeny polynucleotides (106). A subset of the amplified polynucleotides are sequenced to generate sequence reads (108), which are grouped into families each generated from a unique tagged parent nucleotide (110). At the selected locus, the process assigns a per-family confidence score to each family (112). A consensus is then determined using previous reads. This is done by examining previous confidence scores for each family, and if there is a matching previous confidence score, the current confidence score is increased (114). If there is a previous confidence score but it is a mismatch, the current confidence score is not modified in one embodiment (116). In other embodiments, the confidence score is adjusted in a predefined manner for non-matching previous confidence scores. If the family is detected for the first time, the current confidence score can be reduced due to the possibility of a spurious read (118). The process can estimate the frequency of the family at the locus in the set of tagged parent polynucleotides based on the confidence score (120).

[0169] Although temporal information is used in Figures 1-2 to enhance the information of mutation or copy number variation detection, other consensus methods may be applied. In other embodiments, historical comparisons can be used in conjunction with other consensus sequences that map to specific reference sequences to detect cases of genetic mutations. The consensus sequences that map to specific reference sequences can be measured and normalized to control samples. Measurements of molecules that map to reference sequences can be compared across the genome to identify areas in the genome where copy number varies or heterozygosity is lost. Consensus methods include linear or nonlinear methods of constructing consensus sequences (e.g., voting, averaging, statistical, maximum a posteriori or maximum likelihood detection, dynamic programming, Bayesian, hidden Markov or support vector machine methods, etc.), derived from, for example, digital communication theory, information theory or bioinformatics. After the sequence read coverage is determined, a stochastic modeling algorithm is applied to convert the normalized nucleic acid sequence read coverage for each window region into distinct copy number states. In some cases, the algorithm may include one or more of the following: hidden Markov models, dynamic programming, support vector machines, Bayesian networks, trellis decoding, Viterbi decoding, expectation maximization, Kalman filtering methodologies, and neural networks.

[0170] After this, a report can be generated. For example, copy number variation can be reported as a graph showing various positions in the genome and the corresponding increase or decrease or maintenance of copy number variation at each position. Moreover, copy number variation can be used to report a percentage score that shows how much disease material (or nucleic acid with copy number variation) is present in the cell-free polynucleotide sample.

[0171] In one embodiment, the report includes annotations that are useful to the physician. The annotation can include annotating the report with respect to conditions in the NCCN Clinical Practice Guidelines in Oncology™ or the American Society of Clinical Oncology (ASCO) Clinical Practice Guidelines. The annotation can include listing in the report one or more FDA approved drugs for off-label use, one or more drugs listed in the Centers for Medicare and Medicaid Services (CMS) Anticancer Treatment Compendium, and / or one or more experimental drugs found in the scientific literature. The annotation can include linking the listed drug treatment options to bibliographic references that contain scientific information about the drug treatment options. The scientific information can come from peer-reviewed articles in medical journals. The annotation can include using information provided by the Ingenuity® Systems. The annotation can include providing links to information about clinical trials of the drug treatment options in the report. The annotation can include presenting information in a pop-up or fly-over box near the drug treatment options provided in the electronic-based report. The annotation can include adding information to the report selected from the group consisting of one or more drug treatment options, scientific information related to the one or more drug treatment options, one or more links to scientific information regarding the one or more drug treatment options, one or more links to citations of scientific information regarding the one or more drug treatment options, and clinical trial information regarding the one or more drug treatment options.

[0172] As depicted in Figure 4, comparison of sequence coverage to control samples or reference sequences can aid in window-wide normalization. In this embodiment, cell-free DNA is extracted and isolated from readily available bodily fluids, such as blood. For example, cell-free DNA can be extracted using a variety of art-recognized methods, including, but not limited to, isopropanol precipitation and / or silica-based purification. Cell-free DNA can be extracted from any number of subjects, such as subjects free of cancer, subjects at risk of cancer, or subjects known to have cancer.

[0173] After the isolation / extraction step, any of a number of different sequencing operations can be performed on the cell-free polynucleotide sample. The sample can be processed with one or more reagents (e.g., enzymes, unique identifiers (e.g., barcodes), probes, etc.) before sequencing. In some cases, when the sample is processed with a unique identifier such as a barcode, the sample or a fragment of the sample can be tagged with a unique identifier, either individually or in subgroups. The tagged sample can then be used in downstream applications, such as sequencing reactions, thereby allowing individual molecules to be traced back to parent molecules.

[0174] In general, as shown in FIG. 4, mutation detection can be performed on selectively enriched regions of the genome or purified and isolated transcriptomes (302). As described herein, specific regions, including but not limited to genes, oncogenes, tumor suppressor genes, promoters, regulatory sequence elements, non-coding regions, miRNAs, snRNAs, and others, can be selectively amplified from the total population of cell-free polynucleotides. This can be performed as described herein. In one example, multiplex sequencing can be used with or without barcode labeling for individual polynucleotide sequences. In another example, sequencing can be performed using any art-recognized nucleic acid sequencing platform. This step generates multiple genome fragment sequence reads (304). Additionally, a reference sequence is obtained from a control sample taken from another subject. In some cases, the control subject can be a subject known to be free of known genetic variations or diseases. In some cases, such sequence reads can contain barcode information. In other examples, barcodes are not utilized. In yet another example, unique sequence tags are not used.

[0175] After sequencing, the reads are assigned a quality score. The quality score may be an indication of the reads that indicate whether these reads may be useful in subsequent analysis based on a threshold. In some cases, some reads are not of sufficient quality or length to perform the subsequent mapping step. In step 306, the genome fragment reads that meet a specified quality score threshold are mapped to a reference genome or a reference sequence that is known not to contain mutations. After mapping alignment, the sequence reads are assigned a mapping score. The mapping score may be an indication or a read that is mapped back to the reference sequence that indicates whether each position is uniquely mappable or not. In some cases, the reads may be sequences that are independent of the mutation analysis. For example, some sequence reads may originate from contaminant polynucleotides. Sequencing reads with a mapping score of at least 90%, 95%, 99%, 99.9%, 99.99% or 99.999% may be filtered out of the dataset. In other cases, sequencing reads assigned a mapping score of less than 90%, 95%, 99%, 99.9%, 99.99% or 99.999% can be filtered out from the dataset.

[0176] For each mappable base, bases that do not meet a minimum threshold of mappability or low quality bases can be replaced by the corresponding base found in the reference sequence.

[0177] Once read coverage can be confirmed and the variant bases for each read identified relative to the control sequence, the frequency of the variant base can be calculated as the number of reads containing the variant divided by the total number of reads (308), which can be expressed as a ratio for each mappable position in the genome.

[0178] For each base position, the frequency of all four nucleotides, cytosine, guanine, thymine, and adenine, is analyzed relative to the reference sequence (310). A stochastic or statistical modeling algorithm is applied to transform the normalized ratios for each mappable position to reflect the frequency state of each base variant. In some cases, the algorithm may include one or more of the following: hidden Markov models, dynamic programming, support vector machines, Bayesian or probabilistic modeling, trellis decoding, Viterbi decoding, expectation maximization, Kalman filtering methodologies, and neural networks.

[0179] The separate mutation status of each base position can be used to identify base variants with high frequency variance compared to the baseline of the reference sequence. In some cases, the baseline can represent a frequency of at least 0.0001%, 0.001%, 0.01%, 0.1%, 1.0%, 2.0%, 3.0%, 4.0%, 5.0%, 10% or 25%. In other cases, the baseline can represent a frequency of at least 0.0001%, 0.001%, 0.01%, 0.1%, 1.0%, 2.0%, 3.0%, 4.0%, 5.0%, 10% or 25%. In some cases, all adjacent base positions with base variants or mutations can be merged into a segment to report the presence or absence of the mutation. In some cases, various positions can be filtered before merging with other segments.

[0180] After calculating the frequency of variance for each base position, the variant with the greatest deviation for a specific position in the sequence derived from the subject compared to the reference sequence is identified as a mutation.In some cases, the mutation may be a cancer mutation.In other cases, the mutation may be correlated with a disease state.

[0181] Mutations or variants can include genetic abnormalities, including but not limited to single base substitutions, transversions, transitions, inversions, deletions, aneuploidy, partial aneuploidy, polyploidy, chromosomal instability, chromosomal structural changes, chromosomal fusions, gene truncations, gene amplifications, gene duplications, chromosomal damage, DNA damage, abnormal changes in chemical modification of nucleic acids, abnormal changes in epigenetic patterns, and abnormal changes in nucleic acid methylation. In some cases, the mutation can be at most 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, or 20 nucleotides in length. In other cases, the mutation can be at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, or 20 nucleotides in length.

[0182] Next, a consensus is determined using previous reads. This is done by examining previous confidence scores of corresponding bases, and if there is a matching previous confidence score, the current confidence score is increased (314). If there is a previous confidence score but it is a mismatch, in one embodiment the current confidence score is not modified (316). In other embodiments, the confidence score is adjusted in a predefined manner for the non-matching previous confidence scores. If the family is detected for the first time, the current confidence score may be reduced due to the possibility of a spurious read (318). The process then converts the frequency of each base variance into a separate variant state for each base position (320).

[0183] One embodiment renders the stream graph so that it is not x-axis reflective. The modified graph applies a unique scaling to display proportional features. The graph can show the addition of new features over time. The presence or absence of mutations can be reflected in a graphical form showing various positions in the genome and the corresponding increase or decrease or maintenance of the frequency of mutations at each position. Furthermore, mutations can be used to report a percentage score that indicates how much disease material is present in the cell-free polynucleotide sample. Given the known statistics of typical variance in reported positions in non-disease reference sequences, a confidence score can accompany each detected mutation. Mutations can be ranked in order of abundance in subjects or by clinically actionable importance.

[0184] Next, the applications of the technology are detailed. One application is the detection of cancer. A number of cancers can be detected using the methods and systems described herein. Cancer cells, like most cells, can be characterized by their rate of turnover, where older cells die and are replaced by newer cells. Generally, dead cells in contact with the vasculature in a given subject can release DNA or fragments of DNA into the bloodstream. This is also true for cancer cells at various stages of disease. Cancer cells can also be characterized by various genetic variations, such as copy number variations and mutations, depending on the stage of the disease. This phenomenon can be used to detect the presence or absence of cancer in an individual using the methods and systems described herein.

[0185] For example, blood from a subject at risk of cancer can be collected and prepared as described herein to generate a population of cell-free polynucleotides.In one example, this can be cell-free DNA.The disclosed system and method can be used to detect mutations or copy number variations that may exist in certain cancers that exist.The method can be useful for detecting the presence of cancerous cells in the body, despite the absence of symptoms or other characteristics of disease.

[0186] The type and number of cancers that may be detected may include, but are not limited to, blood cancer, brain cancer, lung cancer, skin cancer, nose cancer, throat cancer, liver cancer, bone cancer, lymphoma, pancreatic cancer, skin cancer, intestinal cancer, rectal cancer, thyroid cancer, bladder cancer, kidney cancer, oral cancer, stomach cancer, solid tumors, heterogeneous tumors, homogeneous tumors, and others.

[0187] In early cancer detection, any of the systems or methods described herein can be used to detect cancer, including mutation detection or copy number variation detection.These systems and methods can be used to detect any number of gene variations that can cause or be caused by cancer.These can include, but are not limited to, mutations, mutations, indels, copy number variations, transversions, translocations, inversions, deletions, aneuploidy, partial aneuploidy, polyploidy, chromosomal instability, chromosomal structural changes, gene fusions, chromosomal fusions, gene truncations, gene amplifications, gene duplications, chromosomal damage, DNA damage, abnormal changes in nucleic acid chemical modification, abnormal changes in epigenetic patterns, and abnormal changes in nucleic acid methylation, which are associated with infection and cancer.

[0188] Moreover, the systems and methods described herein can also be used to help characterize certain cancers. The genetic data generated from the systems and methods of the present disclosure can help practitioners better characterize specific forms of cancer. Cancers may be heterogeneous in both composition and stage classification. Genetic profile data can enable characterization of specific subtypes of cancer, which can be important in diagnosing or treating the specific subtype. This information can also provide subjects or practitioners with clues regarding the prognosis of specific types of cancer.

[0189] The systems and methods provided herein can be used to monitor cancer or other diseases in a particular subject. This can allow either the subject or the practitioner to adapt treatment options to match the progression of the disease. In this example, the systems and methods described herein can be used to build a genetic profile of a particular subject's disease progression. In some cases, cancer can progress and become more aggressive and genetically unstable. In other examples, cancer can remain benign, inactive or dormant. The systems and methods of the present disclosure can be useful in determining disease progression.

[0190] Furthermore, the systems and methods described herein may be useful in determining the effectiveness of a particular treatment option. In one example, if the treatment is successful as more cancers die and DNA is shed, the successful treatment option may actually increase the amount of copy number variation or mutation detected in the subject's blood. In another example, this may not occur. In another example, perhaps a particular treatment option may be correlated with the genetic profile of the cancer over time. This correlation may be useful in selecting a treatment method. Moreover, if the cancer is observed to be in remission after treatment, the systems and methods described herein may be useful in monitoring residual disease or disease recurrence.

[0191] The methods and systems described herein may not be limited to the detection of mutations and copy number variations associated with cancer only. Various other diseases and infections can result in other types of conditions that can be suitable for early detection and monitoring. For example, in certain cases, genetic disorders or infectious diseases can cause certain genetic mosaicism in a subject. This genetic mosaicism can cause copy number variations and mutations that can be observed. In another example, the systems and methods of the present disclosure can also be used to monitor the genome of immune cells in the body. Immune cells, such as B cells, can undergo rapid clonal expansion due to the presence of certain diseases. Clonal expansion can be monitored using copy number variation detection to monitor certain immune conditions. In this example, copy number variation analysis can be performed over time to generate a profile of how a certain disease is progressing.

[0192] Additionally, the disclosed systems and methods can also be used to monitor systemic infections themselves, which may be caused by pathogens such as bacteria or viruses. Copy number variation or even mutation detection can be used to determine how much the pathogen population is changing over the course of an infection. This can be particularly important in chronic infections, such as HIV / AIDs or hepatitis infections, whereby the virus can change and / or mutate its life cycle state to a more pathogenic form over the course of an infection.

[0193] Yet another example in which the system and method of the present disclosure can be used is monitoring transplant subjects. Generally, transplanted tissue undergoes some degree of rejection by the body after transplantation. Since immune cells attempt to destroy transplanted tissue, the method of the present disclosure can be used to determine or profile the rejection activity of the host body. This can be useful in monitoring the status of transplanted tissue as well as modifying the course of treatment or prevention of rejection.

[0194] Furthermore, the method of the present disclosure can be used to characterize the heterogeneity of abnormal conditions in a subject, the method includes generating a genetic profile of extracellular polynucleotides in the subject, the genetic profile including multiple data resulting from copy number variation and mutation analysis. In some cases, diseases, including but not limited to cancer, can be heterogeneous. Disease cells may not be identical. In the example of cancer, some tumors contain different types of tumor cells, some cells at different stages of cancer. In other examples, heterogeneity can include multiple foci of disease. Again, in the example of cancer, there may be multiple tumor foci, where perhaps one or more foci are the result of metastasis that has spread from the primary site.

[0195] The methods of the present disclosure can be used to generate or profile fingerprints or sets of data that are the sum of genetic information from different cells in a heterogeneous disease. This data set can include copy number variation and mutation analysis, either alone or in combination.

[0196] Moreover, the systems and methods of the present disclosure can be used to diagnose, prognose, monitor or observe cancer or other diseases of fetal origin, i.e., such methodologies can be used in pregnant subjects to diagnose, prognose, monitor or observe cancer or other diseases in unborn subjects whose DNA and other polynucleotides may circulate with maternal molecules.

[0197] Furthermore, these reports are submitted and accessed electronically via the internet. Analysis of the sequence data occurs at a location other than the subject's location. Reports are generated and transmitted to the subject's location. Via an internet-enabled computer, subjects access reports reflecting their tumor burden.

[0198] A healthcare provider can use the annotated information to select other drug treatment options and / or provide information about the drug treatment options to insurance companies. The method can include, for example, annotating the drug treatment options with respect to conditions in the NCCN Clinical Practice Guidelines in Oncology™ or the American Society of Clinical Oncology (ASCO) Clinical Practice Guidelines.

[0199] The drug treatment options stratified in the report can be annotated in the report by listing additional drug treatment options. The additional drug treatment can be an FDA approved drug for off-label use. Provisions in the Omnibus Budget Reconciliation Act of 1993 (OBRA) require Medicare to cover off-label use of anti-cancer drugs included in standard medical compendia. Drugs used to annotate the list can be found in CMS approved compendias including the National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium™, Thomson Micromedex DrugDex®, Elsevier Gold Standard's Clinical Pharmacology compendium and the American Hospital Formulary Service-Drug Information Compendium®.

[0200] Drug treatment options can be annotated by listing experimental drugs that may be useful in treating cancers with one or more molecular markers of a particular condition. Experimental drugs can be drugs for which in vitro data, in vivo data, animal model data, preclinical trial data, or clinical trial data is available. Data can be found in, for example, American Journal of Medicine, Annals of Internal Medicine, Annals of Oncology, Annals of Surgical Oncology, Biology of Blood and Marrow Transplantation, Blood, Bone Marrow Transplantation, British Journal of Cancer, British Journal of Hematology, British Medical Journal, Cancer, Clinical Cancer Research, Drugs, European Journal of Cancer (formerly the European Journal of Cancer and Clinical Oncology), Gynecologic Oncology, International Journal of Radiation, Oncology, Biology, and Physics, The Journal of the American Medical Association, Journal of Clinical Oncology, Journal of the National Cancer Institute, Journal of the National Comprehensive Cancer Network (NCCN), Journal of Urology, Lancet, Lancet It may be published in the peer-reviewed medical literature found in journals listed in the CMS Medicare Benefit Policy Manual, including Oncology, Leukemia, The New England Journal of Medicine, and Radiation Oncology.

[0201] Drug treatment options can be annotated by providing links to electronic reports that link the listed drugs to scientific information about the drugs. For example, a link can be provided to information about clinical trials of the drug (clinicaltrials.gov). If the report is provided via a computer or computer website, the link can be a footnote, a hyperlink to the website, a pop-up box or a flyover box with information, etc. The report and annotated information can be provided in print form, and the annotation can be, for example, a footnote to a bibliography.

[0202] The information for annotating one or more drug treatment options in the report can be provided by a commercial entity that stores scientific information, e.g., Ingenuity® Systems. A healthcare provider can treat a subject, such as a cancer patient, with an experimental drug listed in the annotated information, and the healthcare provider can access the annotated drug treatment options, retrieve the scientific information (e.g., a printed medical journal article), and submit this (e.g., the printed journal article) to an insurance company along with a request for reimbursement to provide the drug treatment. The physician can use any of a variety of diagnosis-related group (DRG) codes to enable reimbursement.

[0203] The drug treatment options in the report can also be annotated with information about other molecular components in the pathway that the drug affects (e.g., information about drugs that target kinases downstream of the cell surface receptor that is the drug target). The drug treatment options can be annotated with information about drugs that target one or more other molecular pathway components. The identification and / or annotation of pathway information can be outsourced or subcontracted to another company.

[0204] The annotated information may include, for example, a drug name (e.g., FDA approved drugs for off-label use; drugs found in a CMS approved compendium, and / or drugs described in scientific (medical) journal articles), scientific information related to one or more drug treatment options, one or more links to scientific information about one or more drugs, clinical trial information about one or more drugs (e.g., information from clinicaltrials.gov / ), scientific information about the drug, or one or more links to citations of the

[0205] The annotated information can be inserted anywhere in the report. The annotated information can be inserted in multiple locations in the report. The annotated information can be inserted near the section of the report regarding stratified drug treatment options. The annotated information can be inserted on a separate page of the report from the stratified drug treatment options. Reports that do not contain stratified drug treatment options can be annotated with the information.

[0206] The provided methods can also be utilized to investigate the effect of drugs in samples (e.g., tumor cells) isolated from a subject (e.g., a cancer patient). In vitro cultures using tumors from cancer patients can be established using techniques recognized by those of skill in the art.

[0207] The methods provided can also include high throughput screening of FDA approved off-label or experimental drugs using in vitro culture and / or xenograft models.

[0208] The methods provided can also include monitoring tumor antigens to detect recurrence.

[0209] Reports can be generated by mapping the genomic position and copy number variation for subjects with cancer, as shown in Figures 5A and 5B. These reports can be compared with other profiles of subjects with known outcomes to show that a particular cancer is aggressive and resistant to treatment. The subject is monitored and re-examined for a period of time. If at the end of this period the copy number variation profile begins to increase dramatically, this can indicate that the current treatment is not working. Comparisons are made with the genetic profiles of other prostate subjects. For example, if it is determined that this increase in copy number variation indicates that the cancer is progressing, the original treatment regimen prescribed no longer treats the cancer, and a new treatment is prescribed.

[0210] In one embodiment, the system supports the gene panel shown in Figure 9. The gene panel of Figure 9 can be used in the methods and systems of the present disclosure.

[0211] These reports can be submitted and accessed electronically via the internet. Analysis of sequence data occurs at a location other than the subject's location. Reports are generated and transmitted to the subject's location. Via an internet-enabled computer, subjects access reports reflecting their tumor burden (Figures 5A and 5B).

[0212] FIG. 6 is a schematic representation of internet-connectable access to reports of subjects with cancer. The system of FIG. 6 can use a handheld or benchtop DNA sequencer. A DNA sequencer is a scientific instrument used to automate the DNA sequencing process. Given a sample of DNA, a DNA sequencer is used to determine the order of the four bases: adenine, guanine, cytosine, and thymine. The order of the DNA bases is reported as a text string called a readout. Some DNA sequencers can also be considered optical instruments because they analyze light signals originating from fluorescent dyes attached to the nucleotides.

[0213] DNA sequencers can apply the Gilbert sequencing method, which is based on chemical modification of DNA and subsequent cleavage of specific bases, or the Sanger technique, which is based on dideoxynucleotide chain termination. The Sanger method has become popular due to its increased efficiency and low radioactivity. DNA sequencers can use techniques that do not require DNA amplification (polymerase chain reaction-PCR), which speeds up sample preparation before sequencing and reduces errors. In addition, sequencing data is collected from reactions caused by the addition of nucleotides in a complementary strand in real time. For example, DNA sequencers can utilize a method called single molecule real-time (SMRT), according to which sequencing data is generated by light (captured by a camera) that is emitted as nucleotides are added to a complementary strand by an enzyme containing a fluorescent dye. Alternatively, DNA sequencers can use electronic systems based on nanopore sensing technology.

[0214] The data is sent by the DNA sequencer to a computer for processing, either through a direct connection or through the Internet. The data processing aspects of the system can be implemented in digital electronic circuitry, or in computer hardware, firmware, software, or combinations thereof. The data processing device of the invention can be implemented in a computer program product tangibly embodied in a machine-readable storage device for implementation by a programmable processor; the data processing method steps of the invention can be performed by the programmable processor, which executes a program of instructions to perform the functions of the invention by operating on input data and generating output. The data processing aspects of the invention can be advantageously implemented in one or more computer programs executable in a programmable system including at least one programmable processor coupled to receive data and instructions from and communicate data and instructions to a data storage system, at least one input device, and at least one output device. Each computer program can be implemented in a high-level procedural or object-oriented programming language, or in assembly or machine language, if desired; in either case, the language can be a compiled or interpreted language. Suitable processors include, by way of example, both general and special purpose microprocessors. Typically, a processor will receive instructions and data from a read-only memory and / or a random-access memory. Storage devices suitable for a tangible embodiment of computer program instructions and data include all forms of non-volatile memory, including, by way of example, semiconductor memory devices such as EPROM, EEPROM and flash memory devices; magnetic disks, such as internal hard disks and removable disks; magneto-optical disks; and CD-ROM disks. Any of the foregoing may be supplemented by or incorporated in ASICs (application-specific integrated circuits).

[0215] To provide for interaction with a user, the invention can be implemented using a computer system having a display device, such as a monitor or LCD (liquid crystal display) screen for displaying information to a user, and input devices, such as a keyboard, a two-dimensional pointing device, such as a mouse or trackball, or a three-dimensional pointing device, such as a data glove or gyroscopic mouse, by which a user can provide input to the computer system. The computer system can be programmed to provide a graphical user interface through which computer programs interact with a user. The computer system can be programmed to provide a virtual reality, three-dimensional display interface. Computer Control System

[0216] The present disclosure provides a computer control system that is programmed to carry out the method of the present disclosure. Figure 7 shows a computer system 701 that is programmed or otherwise configured to analyze genetic data. The methods described herein for detecting genetic variations below the detection limit can provide more efficient processing of genetic data, thereby improving the functionality of the computer system. For example, the computer system can process genetic data more quickly or efficiently to identify genetic variants (e.g., if the computer system can identify genetic variants below the detection limit, reprocessing of genetic data or processing of additional genetic data may not be necessary).

[0217] The computer system 701 can regulate various aspects of the present disclosure, such as detecting genetic variations below the noise range or detection limit, detecting genetic variations in, for example, nucleic acid molecules, comparing sets of genetic variations, determining diagnostic confidence indices, determining confidence intervals, sequencing nucleic acids, including massively parallel sequencing, grouping sequence read data into families, collapsing grouped sequence read data, determining consensus sequences, etc. The computer system 801 can be a user's electronic device or a computer system located remotely with respect to the electronic device. The electronic device can be a mobile electronic device.

[0218] The computer system 701 includes a central processing unit (CPU, also referred to herein as a "processor" and a "computer processor") 705, which may be a single-core processor, a multi-core processor, or multiple processors for parallel processing. The computer system 701 also includes a memory or memory location 710 (e.g., random access memory, read-only memory, flash memory), an electronic storage unit 715 (e.g., a hard disk), a communication interface 720 (e.g., a network adapter) for communicating with one or more other systems, and peripheral devices 725, such as cache, other memory, data storage, and / or electronic display adapters. The memory 710, the storage unit 715, the interface 720, and the peripheral devices 725 communicate with the CPU 705 via a communication bus (solid lines), such as a motherboard. The storage unit 715 may be a data storage unit (or data repository) for storing data. The computer system 701 may be operatively coupled to a computer network ("network") 730 with the aid of the communication interface 720. Network 730 may be the Internet, an Internet and / or an extranet, or an intranet and / or an extranet in communication with the Internet. Network 730 is, in some cases, a remote communication and / or data network. Network 730 may include one or more computer servers that may enable distributed computing, such as cloud computing. Network 730 may include one or more computer servers that may enable distributed computing, such as cloud computing. Network 730 may implement a peer-to-peer network, in some cases with the aid of computer system 701, which may enable devices coupled to computer system 701 to act as clients or servers.

[0219] The CPU 705 may execute a series of machine-readable instructions, which may be embodied in a program or software. The instructions may be stored in a memory location, such as the memory 710. The instructions may be directed to the CPU 705, which may then program or otherwise configure the CPU 705 to perform the methods of the present disclosure. Examples of operations performed by the CPU 705 may include fetch, decode, execute, and writeback.

[0220] The CPU 705 may be part of a circuit, such as an integrated circuit. One or more other components of the system 701 may also be included in the circuit. In some cases, the circuit is an application specific integrated circuit (ASIC).

[0221] The storage device 715 can store files such as drivers, libraries, and saved programs. The storage device 715 can store user data such as user preferences and user programs. The computer system 701 can include one or more additional data storage devices that, in some cases, are located outside the computer system 701, for example, on a remote server coupled to the computer system 701 over an intranet or the Internet.

[0222] The computer system 701 can communicate with one or more remote computer systems through the network 730. For example, the computer system 701 can communicate with a remote computer system of a user (e.g., a doctor, a researcher, a genetic consultant, a scientist, among others). Examples of remote computer systems include a personal computer (e.g., a portable PC), a slate or tablet PC (e.g., an Apple® iPad®, a Samsung® Galaxy Tab), a telephone, a smart phone (e.g., an Apple® iPhone®, an Android device, a Blackberry®), or a personal digital assistant. A user can access the computer system 701 through the network 730.

[0223] The methods described herein may be implemented by machine (e.g., a computer processor) executable code stored in an electronic storage location of the computer system 701, such as, for example, memory 710 or electronic storage unit 715. The machine executable or machine readable code may be provided in the form of software. During use, the processor 705 may execute the code. In some cases, the code may be read from the storage device 715 and stored in the memory 710 for ready access by the processor 705. In some situations, the electronic storage device 715 may be eliminated and the machine executable instructions are stored in the memory 710.

[0224] The code may be precompiled and configured for a machine having a processor suitable for executing the code, or may be compiled at run time. The code may be provided in a programming language that may be selected to allow the code to be executed in a precompiled or compiled manner.

[0225] Aspects of the systems and methods provided herein, such as computer system 801, can be embodied in programming. Various aspects of the technology can be considered to be "products" or "articles of manufacture," typically in the form of machine (or processor) executable code and / or associated data carried or embodied in some type of machine-readable medium. The machine executable code can be stored in an electronic storage unit, such as a memory (e.g., read-only memory, random access memory, flash memory) or a hard disk. A "storage" type medium can include any and all tangible memory or associated modules of a computer, processor, or the like, such as various semiconductor memories, tape drives, disk drives, etc., that can provide non-transitory storage at any time for software programming. The entire or portions of the software can be communicated at some point via the Internet or various other telecommunications networks. Such communication can, for example, enable loading of the software from one computer or processor to another, for example, from a management server or host computer to a computer platform of an application server. Thus, other types of media that may carry software elements include optical, electrical and electromagnetic waves, such as those used across physical interfaces between local devices, for example, through wired and optical landline networks, and over various air links. The physical elements that carry such waves, such as wired or wireless links, optical links, etc., may also be considered media that carry software. As used herein, unless limited to fixed, tangible "storage" media, terms such as computer or machine "readable medium" refer to any medium that participates in providing instructions to a processor for execution.

[0226] Thus, a machine-readable medium such as a computer-executable code can take many forms, including, but not limited to, a tangible storage medium, a carrier wave medium, or a physical transmission medium. Non-volatile storage media include, for example, optical or magnetic disks, such as any of the storage devices in any computer(s), such as, for example, the databases shown in the figures, that can be used to execute the program. Volatile storage media include dynamic memories, such as the main memory of such computer platforms. Tangible transmission media include coaxial cables; copper wire and optical fibers, including the wires that make up a bus in a computer system. Carrier wave transmission media can take the form of electric or electromagnetic signals, or acoustic or light waves, such as those generated during radio frequency (RF) and infrared (IR) data communications. Thus, common forms of computer readable media include, for example: a floppy disk, a flexible disk, a hard disk, a magnetic tape, any other magnetic medium, a CD-ROM, a DVD or DVD-ROM, any other optical medium, punch cards paper tape, any other physical storage medium having a pattern of holes, RAM, ROM, PROM and EPROM, Flash EPROM, any other memory chip or cartridge, a carrier wave carrying data or instructions, a cable or link which carries such a carrier wave, or any other medium from which a computer can read programming code and / or data. Many of these forms of computer readable media may be involved in carrying one or more sequences of one or more instructions to a processor for execution.

[0227] The computer system 701 can include or be coupled to an electronic display 735 that includes a user interface (UI) 740 for providing a personalized or individualized patient report identifying genomic variations or alterations, which can include, for example, tumor-specific genomic alterations and associated treatment options. Examples of UIs include, without limitation, graphical user interfaces (GUIs) and web-based user interfaces. Data generated and displayed using the user interface (740) can be accessed by users, such as health care professionals, researchers, genetic consultants, or scientists, over a network.

[0228] The disclosed methods and systems can be implemented as one or more algorithms. The algorithms can be implemented as software by execution by the central processing unit 705. The algorithms can perform, for example, sequencing nucleic acids (e.g., massively parallel sequencing), grouping nucleic acid sequences, collapsing grouped nucleic acid sequences, generating consensus sequences, detecting genetic variations, updating diagnostic confidence intervals, annotating sequences, generating reports, and other processes that can include one or more of the following: hidden Markov models, dynamic programming, Bayesian networks, trellis decoding, Viterbi decoding, expectation maximization, Kalman filtering methodology, and neural networks.

[0229] The following examples are offered by way of illustration and not by way of limitation. EXAMPLES

[0230] FIG. 8 shows a graph of the frequency of base changes (compared to the reference genome) detected in DNA samples along 70 kb of sequence of multiple oncogenes that were amplified and sequenced using a protocol suitable for Illumine sequencing. Control DNA with sequence variants at known positions was spiked into the samples at a low percentage. These variants are represented by dark circles. Variants occurring at log 0 (100%) or log -0.3 (0.5 or 50%) represent homozygous or heterozygous loci. Variants at less than log -2 (less than 1%) occur in the noise range of this system and may represent sequencing errors (noise) or real variants (information). For any variants detected in the noise range, it may not be possible to determine whether the variant represents noise or information. In the "noise", there is less confidence that the base call at the mutant position represents information (real mutant) and not noise. However, if the control DNA is spiked into a second sample, it should reappear at a similar frequency. In contrast, the probability that an error is detected again at the same locus is a function of the error rate, which is unlikely to be seen. Independent detection of the same variant increases the probability that information rather than noise is detected, providing increased confidence that the cancer diagnosis is correct.

[0231] To the extent that sequencing errors are the result of chance, the probability of detecting the same sequencing error multiple times may be exponentially smaller than detecting it once. Thus, if a particular signal is detected multiple times, it is likely information rather than noise. This feature can be used to increase the probability that genetic variants detected at low levels represent real polynucleotides or sets of polynucleotides rather than sequencing artifacts.

[0232] In one example, a signal representative of a disease state is detected in multiple instances. In certain embodiments, the signal is a polynucleotide with a cancer-associated somatic mutation or a cancer-associated copy number variation. Repeated detection of the signal increases the probability that the signal represents information rather than noise. Repeated instances include, without limitation, (1) repeated testing of the same sample, (2) testing of two samples taken from a subject at the same time, or (3) testing of two samples taken from a subject at different times. Determining the increased probability is particularly useful when the first detected signal is at a level that cannot be reliably distinguished from noise. The method of this disclosure is useful, among other things, in monitoring a subject over time for early detection of a disease state, for example, when repeated testing detects a disease state at a level that is too low for a single test to reliably diagnose the disease state.

[0233] In another example describing covariate variants associated with lung cancer, signals associated with high confidence variations are detected below the detection limit. If an EGFR L858R activating mutation is detected, the detection threshold for covariate resistance mutations, EGFR T790M resistance mutations, is relaxed. Independent detection of the activating or driver mutation increases the confidence that the covariate variant within the detection threshold will also be detected.

[0234] The methods and systems of the present disclosure may be combined with other methods and systems, such as those described in Patent Cooperation Treaty (PCT) Patent Publication Nos. WO / 2014 / 039556, WO / 2014 / 149134, WO / 2015 / 100427, and WO / 2015 / 175705, each of which is incorporated by reference in its entirety.

[0235] While preferred embodiments of the present invention have been shown and described herein, it will be apparent to those skilled in the art that such embodiments are provided by way of example only. It is not intended that the present invention be limited by the specific examples provided in the specification. Although the present invention has been described with reference to the above specification, the description and illustration of the embodiments herein are not intended to be construed in a limiting sense. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the present invention. Furthermore, it should be understood that all aspects of the present invention are not limited to the specific depictions, configurations, or relative proportions shown herein, which depend upon a variety of conditions and variables. It should be understood that various alternatives to the embodiments of the present invention described herein can be used in the practice of the present invention. It is therefore contemplated that the present invention shall cover any such alternatives, modifications, variations, or equivalents. It is intended that the following claims define the scope of the present invention, and that methods and structures within the scope of these claims and their equivalents are covered therein.

Claims

1. 1. A system including one or more computer processors and associated memory, the memory comprises a non-transitory computer readable medium comprising machine executable code that, upon execution on the one or more computer processors, performs a method for detecting trends in abundance of cancer polynucleotides over time in a biological sample from a subject; The method comprises: determining a frequency of said cancer polynucleotide at each of a plurality of time points; determining an error range for the frequency at each of the plurality of time points to provide at least a first error range at a first time point and a second error range at a second time point after the first time point; (1) determining whether the first error range overlaps with the second error range, the overlap indicating stability in the frequency of the cancer polynucleotide at the multiple time points; (2) determining whether the second error range is larger than the first error range and therefore represents an increase in the frequency of the cancer polynucleotide at the multiple time points; or (3) determining whether the second error range is smaller than the first error range and therefore represents a decrease in the frequency of the cancer polynucleotide at the multiple time points, wherein the error ranges are provided along with confidence intervals.

2. The system of claim 1 , wherein the cancer polynucleotide is a deoxyribonucleic acid (DNA) molecule.

3. The system of claim 2 , wherein the DNA molecule is cell-free DNA.

4. The system of claim 3 , wherein the cell-free DNA is derived from a blood sample, a plasma sample, or a serum sample.

5. The system of claim 1 , wherein the cancer polynucleotide comprises one or more genetic variations.

6. 6. The system of claim 5, wherein each of the one or more genetic variations is selected from the group consisting of single base substitutions, copy number variations, indels, gene fusions, transversions, transitions, inversions, deletions, aneuploidy, partial aneuploidy, polyploidy, chromosomal instability, chromosomal structural alterations, chromosomal fusions, gene truncations, gene amplifications, gene duplications, chromosomal lesions, DNA lesions, abnormal changes in chemical modifications of nucleic acids, abnormal changes in epigenetic patterns, and abnormal changes in nucleic acid methylation.

7. The system of claim 1 , wherein the frequency at each of the plurality of time points is determined by sequencing a nucleic acid molecule in a biological sample of the subject.

8. The system of claim 7 , wherein the method comprises generating a set of sequence read data at each of the multiple time points.

9. The system of claim 8 , wherein the sequence reads are filtered by requiring the sequence reads to meet a quality threshold.

10. The system of claim 1 , wherein the biological sample is a blood sample, a plasma sample, or a serum sample.

11. 1. A method for detecting trends in the amount of a cancer polynucleotide over time in a biological sample from a subject, comprising: determining, using one or more programmed computer processors, a frequency of said cancer polynucleotides at each of a plurality of time points; determining an error range for the frequency at each of the plurality of time points to provide at least a first error range at a first time point and a second error range at a second time point after the first time point; (1) determining whether the first error range overlaps with the second error range, the overlap indicating stability in frequency of the cancer polynucleotide at the multiple time points; (2) determining whether the second error range is larger than the first error range and therefore represents an increase in frequency of the cancer polynucleotide at the multiple time points; or (3) determining whether the second error range is smaller than the first error range and therefore represents a decrease in frequency of the cancer polynucleotide at the multiple time points, wherein error ranges are provided along with confidence intervals.

12. 12. The method of claim 11, wherein the cancer polynucleotide is a deoxyribonucleic acid (DNA) molecule.

13. The method of claim 12, wherein the DNA molecule is cell-free DNA.

14. 14. The method of claim 13, wherein the cell-free DNA is derived from a blood sample, a plasma sample, or a serum sample.

15. 12. The method of claim 11, wherein the cancer polynucleotide comprises one or more genetic variations.

16. Each of the one or more genetic variations is selected from the group consisting of single base substitutions, copy number variations, indels, gene fusions, transversions, transitions, inversions, deletions, aneuploidy, partial aneuploidy, polyploidy, chromosomal instability, chromosomal structural alterations, chromosomal fusions, gene truncations, gene amplifications, gene duplications, chromosomal lesions, DNA lesions, abnormal changes in chemical modifications of nucleic acids, abnormal changes in epigenetic patterns, and abnormal changes in nucleic acid methylation. The method of claim 15 .

17. 12. The method of claim 11, wherein the frequency at each of the plurality of time points is determined by sequencing a nucleic acid molecule in a biological sample of the subject.

18. 20. The method of claim 17, comprising generating a set of sequence read data at each of the multiple time points.

19. 20. The method of claim 18, wherein the sequence reads are filtered by requiring the sequence reads to meet a quality threshold.

20. 12. The method of claim 11, wherein the biological sample is a blood sample, a plasma sample, or a serum sample.

Citation Information

Patent Citations

  • Mutational analysis of plasma DNA for cancer detection

    WO2013190441A2